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ABSTRACT 
 
 
 Angiotensin II (Ang II) activates cytosolic phospholipase A2α and releases 
arachidonic acid (AA) from tissue phospholipids. AA metabolites mediate or modulate 
one or more reno-cardiovascular effects of this peptide and have been implicated in 
hypertension. Since AA release is the rate limiting step in eicosanoid production, it is 
possible that cPLA2α might play a central role in the development of Ang II-induced 
hypertension. To test this hypothesis, we investigated the effect of Ang II infusion for 13 
days by micro-osmotic pumps (700 ng/kg/min), on systolic blood pressure and associated 
pathophysiological changes in wild type (cPLA2α+/+) and cPLA2α-/- mice. Ang II infusion 
increased systolic blood pressure in cPLA2α+/+ but not in cPLA2α-/- mice. Ang II induced 
increase in systolic blood pressure was also abolished by the AA metabolism inhibitor, 
5,8,11,14-eicosatetraynoic acid in cPLA2α+/+ mice. Ang II infusion in cPLA2α+/+ mice 
increased cardiac and renal cPLA2 activity, resulted in cardiovascular and renal 
dysfunction, caused cardiovascular remodeling, endothelial dysfunction, increased 
vascular reactivity and compromised renal hemodynamics in cPLA2α+/+ mice; these 
events were diminished in cPLA2α-/- mice. Ang II also increased cardiac and renal 
infiltration of F4/80+ macrophages and CD3+ T lymphocytes, caused cardiac fibrosis and 
produced cardiovascular and renal oxidative stress and end organ damage, in cPLA2α+/+ 
but not cPLA2α-/- mice. Infusion of Ang II increased cardiac ER stress and activity of 
ERK1/2 and cSrc in cPLA2α+/+, but not cPLA2α-/- mice. These data suggest that Ang II-
induced hypertension and associated reno-cardiovascular pathophysiological changes are 
mediated by cPLA2α activation, most likely through the release of AA and the generation 
of pro-hypertensive eicosanoids. 
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CHAPTER 1.    INTRODUCTION 
 
 
1.1 Strategy and Significance 
 
 Cardiovascular disease is prevalent in modern societies, and hypertension is the 
leading cause of cardiovascular morbidity/mortality. According to the latest AHA 
statistics, in the United States, 76.4 million (33.5%) individuals ≥ 20 years of age are 
hypertensive, and more than 70% of patients who suffer a heart attack, stroke, or 
congestive heart failure are hypertensive.1 Moreover, hypertension is a major risk factor 
for ischemic heart disease and renal failure. Clearly, physicians need better approaches to 
prevent hypertension-related morbidity and mortality; thus, the focus of this study is to 
explore the potential of a promising therapeutic target, i.e., cytosolic phospholipase A2? 
(cPLA2?). 
 
 cPLA2? is a subset of a large family of phospholipase enzymes that release fatty 
acids from the second carbon of phospholipids. Mammals have at least 15 groups of 
PLA2 enzymes, which have been classified into four groups based on structure, catalytic 
mechanism, localization, and evolutionary relationship: Ca2+-dependent cPLA2?, Ca2+-
independent PLA2 (iPLA2), secretory PLA2 (sPLA2), and platelet-activating 
acetylhydrolases.2 cPLA2? is widely expressed and constitutively active; however, 
nanomolar levels of Ca2+ and various mitogen-activated protein kinases and 
calcium/calmodulin-dependent kinase II (CAMKII) via phosphorylation regulate cPLA2? 
activity.3-6 cPLA2α has been implicated in a number of physiological and 
pathophysiological conditions including allergy, asthma, brain ischemia injury, and 
arthritis.7  
 
 With regard to hypertension and cardiovascular disease, PLA2 activity is 
increased in the renal medulla and cortex of stroke-prone, spontaneously hypertensive 
rats (SHR),8 and a recent study demonstrated that cPLA2α gene disruption prevented L-
NG-nitroarginine methyl ester (L-NAME), an inhibitor of nitric oxide synthesis-induced 
hypertension.9 But the most compelling reason for focusing on cPLA2α is that this 
enzyme is activated by numerous blood pressure (BP) regulating-hormones and is highly 
selective for arachidonic acid (AA)-containing phospholipids. Thus, cPLA2α is a major 
center of convergence for the transduction of hormone signaling via generation of 
eicosanoids, which represent a complex family of AA metabolites that are critically 
engaged in BP regulation and end organ damage. In view of the release of AA from 
tissue lipids by neuro-humoral agents and AA’s metabolism via multiple pathways into 
pro- and anti-hypertensive eicosanoids, it appears that the effect/levels of pro-
hypertensive eicosanoids predominate during hypertension. Importantly, the production 
of pro-hypertensive eicosanoids depends upon the release of AA by cPLA2α from tissue 
lipids, a rate-limiting step in the synthesis of eicosanoids. Thus, activation of cPLA2α by 
angiotensin (Ang) II and other vasoactive agents could be a key step in the development 
of hypertension and associated cardiovascular and renal pathophysiology. 
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 Thus the hypothesis of my study is that Group IV cPLA2α is critical for the 
development of Ang II-induced hypertension and its pathogenesis and associated target 
organ damage. To test this hypothesis, the following are the aims of this study. 
 
 
1.2 Specific Aims 
 
 
1.2.1 Aim 1. To Determine the Contribution of cPLA2α to Ang II-Induced 
Hypertension and Associated Cardiovascular Pathophysiology 
 
Rationale: Ang II activates one or more phospholipases. However, AA released in 
cardiovascular and renal tissues and infiltration of macrophages is primarily due to 
activation of cPLA2?.3,10,11 AA and/or its metabolites activate nicotinamide dinucleotide 
phosphate (NADPH) oxidase and generate reactive oxygen species (ROS) in the 
cardiovascular system, both of which have been implicated in the development of 
hypertension and cardiovascular and renal dysfunction.12-16 These observations, and our 
preliminary data that the inhibitor of AA metabolism, 5,8,11,14-eicosa-tetraynoic acid 
(ETYA), prevents Ang II-induced increase in systolic blood pressure (SBP) and that 
cPLA2? gene disruption in mice minimizes Ang II-induced hypertension, cardiac 
dysfunction as determined by echocardiography, and cardiac fibrosis and cardiovascular 
oxidative stress as indicated by increased dihydroethidium (DHE) staining have led us to 
the following hypothesis:   
 
cPLA2? is critical for the development of Ang II-induced hypertension, 
hypertrophy, and activation of NADPH oxidase, generation of ROS, cardiovascular 
dysfunction and fibrosis. 
 
 
1.2.2 Aim 2. To Investigate if cPLA2α Is Essential for Renal Dysfunction and End 
Organ Damage Associated with Ang II-Induced Hypertension 
 
Rationale: To determine the role of cPLA2? in renal pathophysiology associated 
with hypertension, I have compared the effects of Ang II on kidney structure and function 
in cPLA2?+/+ versus cPLA2?-/- mice. The renin-angiotensin system (RAS) plays an 
important role in regulating renal function, and alterations in renal function promote 
development of hypertension, which in turn leads to renal damage. Although cPLA2? 
gene disruption in mice does not alter basal renal function, except in older mice (>40 
weeks) that exhibit a urinary concentrating defect, it is not known if cPLA2? contributes 
to renal dysfunction, inflammation, and end organ damage associated with Ang II-
induced hypertension. My data shows that cPLA2? gene disruption results in the loss of 
cPLA2 expression and, consequently, Ang II-induced phosphorylation and prevents 
proteinuria, renal fibrosis, and oxidative stress. Thus, my second hypothesis is: 
 
cPLA2? is crucial for renal dysfunction, activation of NADPH oxidase, 
generation of ROS, and end organ damage associated with Ang II-induced hypertension.  
 3 
CHAPTER 2.    LITERATURE REVIEW 
 
 
2.1 Regulation of Arterial Blood Pressure 
 
The main function of the cardiovascular system is to meet the demands of tissue 
perfusion by providing oxygen and nutrients and eliminating waste products. These are 
achieved by difference in pressures across the arterial and venous network. The driving 
force of this blood flow is called mean arterial pressure (MAP), denoted as Pa (arterial 
pressure)  
 
Pa = cardiac output (CO) x total peripheral resistance (TPR) 
 
In order to perform the vital function of tissue perfusion, MAP must at all times 
be maintained at a high set point of approximately 100 mmHg. This is achieved by two 
major regulatory systems: (i) baroreceptor reflex and (ii) renin angiotensin-aldosterone 
system.  
 
 
2.1.1 Baroreceptor Reflex 
 
Baroreceptors play an essential role in stabilizing perfusion pressure during 
altered or disturbed circulatory homeostasis by specific neuronal17,18 or hormonal 
adjustments19,20 via changes in sympathetic and parasympathetic output signals to the 
heart and sympathetic output to the vasculature. These responses are processed by 
specialized mechanoreceptors often referred to as stretch receptors located in the aortic 
arch and carotid sinus. At resting BP levels, the baroreceptor afferents deliver tonic 
excitatory input to the neurons in the nucleus tractus solitarius (NTS)21 where the 
glossopharyngeal and vagus nerve fibers synapse. The NTS is the site of afferent 
baroreceptor inputs whereas the rostral ventrolateral medulla (RVLM) is the site for 
output of the efferent sympathetic nerve activity.22 The RVLM also receives input signals 
from other areas that are linked to baroreceptors: the medullary lateral tegmental field23 
and the ventrolateral periaqueductal gray.24 The outflow of the neurons of RVLM is 
harmonious with cardiac rhythm. Thus, baroreceptor activation decreases the activity of 
these neurons. It has been demonstrated that sensitivity of the baroreceptor reflex appears 
to be directly related to the neuronal activity within the pressure region of the RVLM.25  
 
An increase in Pa is sensed as an increase in stretch in the blood vessel that results 
in an increased firing rate. In order to restore BP to normal, parasympathetic activity 
increases and sympathetic activity decreases resulting in a decrease in heart rate and 
contractility, and a decrease in venous and arteriolar constriction, together resulting in 
decreased CO and TPR and increased unstressed volume. The operating point of reflex 
and its sensitivity are the key determinants of baroreceptor function.22 These are often 
altered during various physiological and pathophysiological conditions such as 
hypertension,26 sleep,27 aging,28 altered thermoregulation,29 and pregnancy.30 In spite of 
such a vigilant system, sustained increased or decreased Pa may result in alteration of the 
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afferent signal as seen in patients suffering from essential hypertension, wherein the set 
point is reset to a higher level of Pa.31  
 
 
2.1.2 The Renin Angiotensin System 
 
 
2.1.2.1 The Historic Timeline of the Renin Angiotensin System (RAS)  
 
It wasn’t until Tigerstedt and Bergmann, in 1898 published their study detailing 
the existence of renin, a heat labile substance extracted from rabbit renal cortex.32 Their 
idea that renin is the humoral pressor agent, was widely criticized by many until in 1934, 
when Goldblatt et al. demonstrated that renal ischemia could result in hypertension.32 
They further showed that renin, through its proteolytic action, cleaved angiotensinogen, a 
short-lived heat labile peptide, to generate angiotensin, which was then called angiotonin 
or hypertensin.32 Almost two decades later, Ang I and Ang II were discovered by Skeggs 
and colleagues.33 They successfully demonstrated that angiotensin converting enzyme 
(ACE) cleaved Ang I to generate Ang II.34 Shortly after, the work of many other 
investigators led to the discovery that Ang II also stimulates the release of aldosterone, 
the master regulator of Na+-K+ balance,35 and thus evolved the concept of the RAS. 
 
 
2.1.2.2 The Major Players of the RAS  
 
The discovery of renin as the rate limiting pressor substance gave impetus to 
further research that led to the emergence of new frontiers. RAS system has become the 
most well studied subject in the field of cardiovascular research and has since been 
recognized as the master regulator of BP and fluid homeostasis. The afferent arteriole of 
the glomerulus is lined by specialized smooth muscle cells called the juxtaglomerular 
(JG) cells that synthesize renin in its preprohormone form. Clevage of 43 amino acids 
from its N terminal results in the formation of active renin, an aspartyl protease that is 
stored in the granules of the JG cells.36 Renin release is governed by four inter related 
factors: 1) changes in perfusion pressure sensed by the renal baroreceptors in the afferent 
arteriole, 2) alterations in the NaCl load sensed by the macula densa cells, 3) changes in 
sympathetic nerve activity, and 4) negative feedback mechanism by Ang II directly on 
the JG cells.37 Renin is not only synthesized by the kidneys but also by adipose tissue, 
adrenal gland, ovaries, brain, and possibly heart and the vasculature; the synthesis and 
regulation of renin in other tissues is not well understood.36 The action of renin (Figure 
2.1) on angiotensinogen, which is produced primarily by the liver to generate the 
biologically inert decapeptide Ang I, is the rate limiting step in the RAS cascade. ACE 
which is localized mostly in various cell types such as vascular endothelial cells and 
microvillar brush border of epithelial cells then hydrolyses Ang I by cleaving the C- 
terminal dipeptide to form the biologically active and potent vasoconstrictor, Ang II, an 
octapeptide. ACE also metabolizes many other peptides including bradykinin and kallidin 
to its inactive state.38 It is well-established that Ang II is the most important player of the 
RAS; however, there are other metabolites of Ang that serve important biological  
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Figure 2.1 Angiotensin metabolism pathway 
 
Reprinted with permission. Conti S, Cassis P, Benigni A. Aging and the renin-
angiotensin system. Hypertension. 2012;60:878-883.39 
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functions too. Ang III, a heptapeptide, formed by the removal of amino acids from the N-
terminal of Ang II, present in the central nervous system, may play a role in tonic BP 
maintenance and hypertension.40 Further enzymatic degradation of Ang III results in the 
generation of Ang IV, a hexapeptide. Not only do the metabolites of Ang II serve specific 
function, the peptides generated at the C-terminal in this process by stepwise enzymatic 
cleavage also tend to have specific biological activity. One such important fragment 
formed is Ang 1-7, generated by the cleavage of Ang II by the carboxypeptidase, ACE 2. 
Ang 1-7, by binding to the Mas receptor, acts as a vasodilator and has been implicated in 
promoting natriuresis, anti-proliferation and cardio protection.40,41 Thus, the balance 
between ACE and ACE 2 is of critical importance in maintaining Ang II levels.42 
 
Of all the components of the RAS, Ang II is the most important effector 
responsible for a multitude of physiological and pathophysiological actions. Four Ang 
receptors have been discovered so far.41 Most of the effects of Ang II are mediated via 
angiotensin type 1(AT1) receptor (R), whereas the AT2R might mediate a counter- 
regulatory mechanism by inhibiting the actions of Ang II.43 The function of AT3R is not 
well known, while AT4R is thought to mediate the release of plasminogen activator 
inhibitor-1.41 
 
 
2.1.2.3 Ang II Signal Transduction 
 
Ang II not only plays an important role in regulating cardiovascular and renal 
homeostasis, it is also involved in various cardiovascular diseases including hypertension, 
atherosclerosis, restenosis and heart failure. In spite of extensive ongoing research, the 
contribution of Ang II to these pathologies remains obscure. The functions of Ang II are 
mediated by at least two of the four, 7 transmembrane G-protein coupled receptors; AT1 
and AT2. Most of the actions of Ang II that are predominantly located in vascular smooth 
muscle cells (VSMC) are mediated via AT1R and on activation, promote hypertrophy, 
hyperplasia, proliferation and migration of VSMC,44 vasoconstriction, and aldosterone 
release.45 Increased Ang II levels results in increased expression of AT1R, however, 
sustained or chronic Ang II exposure causes downregulation of the receptors. In spite of 
this tight negative feedback regulation, under certain pathological conditions including 
hyperlipidemia,46 and hyperinsulinemia,47AT1Rs are upregulated. 
  
On activation by Ang II, AT1R generates second messengers including inositol 
triphosphate (IP3), diacylglycerol (DAG), and ROS via its interaction with several 
heterotrimeric G proteins. It also activates intracellular protein kinases such as Ser/Thr 
kinases, tyrosine kinases, mitogen activated protein kinase (MAPK) family, and protein 
kinase C (PKC) isoforms.48-51 Binding of IP3 to its receptors on sarcoplasmic reticulum 
results in calcium efflux into the cytoplasm. Ca2+ released, binds to calmodulin and 
results in phosphorylation of myosin light chain via activation of myosin light chain 
kinase. This promotes interaction between actin and myosin resulting in smooth muscle 
cell contraction.52 DAG also activates PKC, which contributes to the Ras/Raf/MEK/ERK 
pathway by which Ang II promotes hypertrophy.53 Ang II also phosphorylates PLA2 and 
releases AA, which is metabolized to various vasoactive eicosanoids. (discussed later) 
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Another important signaling molecule is ROS, generated via NADPH oxidase. In 
VSMC, Ang II activates membrane NADPH oxidase to produce ROS via upstream 
mediators Src/EGFR/PI3K/Rac-1.54,55 Several biological actions of Ang II-mediated 
effects are ROS dependent. One of the most well studied outcomes of Ang II-induced 
ROS production is the inactivation of nitric oxide (NO), resulting in endothelial 
dysfunction.56,57 It has been reported that ROS can cause inflammation of the vasculature 
by recruiting monocytes, macrophages, and T cells at sites of endothelial damage by 
promoting release of cytokines and leukocyte adhesion molecules.58 
 
MAPKs have long been identified as players in the Ang II signal transduction 
cascade. They have been involved in an array of functions including gene expression, 
protein synthesis and metabolism, transport, volume regulation, and growth.59 Studies 
have demonstrated that Ang II activates MAPKs such as extracellular signal regulated 
kinases (ERK1/2), c-Jun N-terminal kinases (JNK), and p38 that are involved in VSMC 
proliferation, differentiation, migration, and fibrosis.60,61 Touyz et al showed that Ang II-
induced VSMC contraction, mediated via ERK signaling may result in increased 
intracellular Ca2+.62 Evidence suggests that activation of ERK1/2 and Akt/PKB inhibits 
apoptosis63-65 and, through regulation of PHAS-1, is involved in cell growth and protein 
synthesis.66 Ang II-induced ERK1/2 activation results in increased gene expression of 
anti-apoptotic transcription factors, c-fos and c-jun, that form the AP-1 complex and 
promote cell differentiation, migration, and adhesion.67 Enhanced ERK1/2 activation has 
been implicated in hypertension and end organ damage.68 In addition to ERK1/2, Ang II 
also activates p38 MAPK, implicated in ROS production via stimulation of NADPH 
oxidase.69  
 
Non-receptor tyrosine kinases also participate in Ang II-induced cellular effects. 
cSrc has emerged as a key second messenger in Ang II-mediated effects. Downstream, 
cSrc activates Ras, FAK, JAK/STAT, and PLC-γ and results in sustained Ca2+ release.70 
cSrc also plays a role in Ang II-induced focal adhesion complex formation and actin 
bundling in VSMC71 and, thus, is responsible for reorganization of the cytoskeleton 
matrix leading to remodeling. Stimulation of AT1R also results in activation of the 
JAK/STAT pathway, which results in gene transcription of early response genes 
including c-fos and myc.71  
 
Receptor tyrosine kinases including platelet derived growth factor (PDGF), 
epidermal growth factor (EGF) are also involved in Ang II-induced hypertrophy. PDGFs 
have been well documented in the pathogenesis of vascular disease by promoting VSMC 
proliferation and migration.72-74 Linseman et al. demonstrated cross talk between AT1R 
and PDGF receptor in VSMC. They showed that stimulation of VSMC with Ang II 
resulted in phosphorylation of Shc and formation of the Shc-Grb2 complex, which further 
activates cSrc75 that has been previously implicated in Ang II-induced contractile 
responses.76 Another major mechanism by which Ang II triggers growth related signaling 
pathway is transactivation of the EGF receptor in a Src dependent manner that occurs in 
the cholesterol rich domains in the caveolae.77,78 This further leads to activation of the 
PI3K/PDK1/Akt1 and the Ras/Raf/ERK pathways via HB-EGF-induced dimerization and 
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autophosphorylation of EGFR, resulting in growth, hypertrophy, survival, and 
inflammation.79 
 
 
2.2 Pathogenesis of Hypertension 
 
Uncontrolled hypertension results in approximately 7.6 million premature deaths 
per year and is now the number one risk factor for cardiovascular deaths1 The prevalence 
of hypertension has increased with the increase in life expectancy, more so in developed 
nations where the problem seems to be worse compared to developing countries where 
only a small fraction of the population develops hypertension. In the United States alone, 
50% of the population between 60-70 years old and 75% over the age of 70, suffer from 
hypertension.1 Despite an extensive body of evidence and advances in medicine, 
hypertension remains a poorly controlled condition. Primary or essential hypertension, 
accounts for 95% of all cases of hypertension for which there is no secondary cause. 
 
 
2.2.1 Renin Angiotensin Aldosterone System  
 
The renin angiotensin aldosterone system (RAAS) (Figure 2.2) is probably the 
most powerful hormone system regulating BP. As explained earlier, Ang II is the most 
potent vasoconstrictor and plays a role in both the long and short term regulation of BP. It 
helps in maintaining acute blood volume and sodium depletion in times of physiological 
crisis.80 The long term effects of Ang II on BP are interrelated with volume homeostasis 
through direct and indirect effects on the kidney; however, high salt intake can be a major 
game changer and can reduce the effectiveness of various RAAS blockers.80 High levels 
of Ang II, attenuate the ability of the kidneys to excrete salt and impair pressure 
natriuresis, thereby resulting in increased BP to maintain sodium balance.  
 
The mechanisms that mediate the potent anti-natriuretic effects of ANG II include 
direct and indirect effects to increase tubular reabsorption as well as renal hemodynamic 
effects.81 Volume depletion and/or under perfusion of kidneys such as sodium depletion, 
hemorrhage, or heart failure, result in activation of RAAS, which leads to aldosterone 
secretion, resulting in salt and water retention by direct effects on hemodynamics and 
epithelial transport. Ang II brings about a reduction in renal blood flow and peritubular 
capillary hydrostatic pressure and increases peritubular colloid osmotic pressure by 
constricting efferent arterioles; these actions result in increased filtration fraction, thus 
facilitating an increase in the driving force for fluid reabsorption across tubular epithelial 
cells.81 At very low concentrations, Ang II, by acting on the luminal membrane of the 
proximal tubules, stimulates Na+-H+ exchanger, and, on the basolateral membrane, 
increases the activity of Na+-K+-ATPase, as well as Na+-HCO3 cotransport.81,82 Ang II 
also mediates its effects on loop of Henle, macula densa, and distal nephron segments. It 
stimulates bicarbonate reabsorption on loop of Henle and promotes Na+-K+-2Cl- transport 
in the medullary thick ascending loop of Henle.82,83 In the distal nephron segments, Ang 
II facilitates Na+-ATPase activity as well as epithelial Na channel activity in the cortical 
collecting ducts.82,83 
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Figure 2.2 Interplay of the renin angiotensin aldosterone system in BP 
maintenance and homeostasis 
 
Reprinted with permission. Vinay Kumar AKA, Jon C. Aster, Nelson Fausto. Robbins & 
Cotran Pathologic Basis of Disease, 8th edn. Saunders, 2009, page 496.84  
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Not only does Ang II regulates BP via renal sodium reabsorption, it does so 
through its potent ability to cause vasoconstriction that is mostly confined, but not limited 
to post glomerular efferent arterioles. Low levels of Ang II produce an increase in 
glomerular filtration rate (GFR) by constricting efferent arteriole but high Ang II levels 
constrict both efferent and afferent arterioles resulting in a decrease in GFR. During 
hemorrhage, when kidney perfusion in threatened, RAAS is activated, to prevent 
excessive reduction in BP, and high levels of Ang II constrict both efferent and afferent 
arterioles to decrease GFR and renal blood flow. 
 
 
2.2.2 Aldosterone 
 
Aldosterone, another powerful hormone, is involved in BP regulation via sodium 
retention and potassium excretion and thus plays an important role in renal pressure 
natriuresis and has functions similar to those of Ang II. The role of aldosterone in human 
hypertension has recently gained a lot of attention, because 20% of hypertensive patients 
suffer from primary aldosteronism.85 Aldosterone is synthesized within the zona 
glomerulosa of adrenal cortex and acts primarily on the principal cells of the distal 
tubules, cortical collecting tubules and collecting ducts. Aldosterone binds to 
mineralocorticoid receptors (MR) and exerts both genomic and non-genomic effects. It 
promotes transcription of certain target genes and stimulates synthesis of Na+-K+-ATPase 
pump on the basolateral epithelial membrane and activates amiloride-sensitive sodium 
channels on the luminal side of the epithelial membrane,86 which results in increased 
sodium current in the principal cells of the cortical collecting tubule and also stimulates 
Na+-K+ exchanger.86,87 Low sodium intake triggers increased aldosterone release to curb 
sodium loss to prevent reduction in BP and high sodium intake inhibits aldosterone 
secretion in an attempt to prevent sodium retention and lower BP. MR antagonism is 
emerging as a therapeutic tool for treating hypertension and associated end organ 
damage.85 
 
 
2.2.3 Endothelin 
 
Endothelial dysfunction resulting from an altered balance between endothelial 
derived relaxing and contracting factors has been observed in many forms of 
experimental and human hypertension. One such potent constricting factor is endothelin 
(ET)-1. ET-1 can activate ET type A (ETA) receptor and elicit a hypertensive response or 
it can activate ET type B (ETB) receptor and elicit an antihypertensive response, thus, the 
nature of response produced by ET depends on the type of receptor it acts on.  
 
Endothelin, via ETA receptor mostly localized on VSMC, produces systemic and 
renal vasoconstriction, impairs pressure natriuresis and increases BP and could contribute 
to progressive renal injury. ET-1 stimulates contraction of VSMC and mesangial cell  
resulting in decreased GFR and renal blood flow and chronic actions of ET-1 may also 
lead to renal mesangial cell proliferation, VSMC hypertrophy and remodeling.88,89 
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Several studies have shown that ETB activation by ET-1 on the other hand, causes 
vasodilation, enhances pressure natriuresis and decreases BP. ETB  deficient rats exhibit 
severe salt sensitive hypertension90 and mice develop endothelial dysfunction 
independent of salt loading.91  
 
 
2.2.4 Oxidative Stress 
 
It is well established that ROS contributes to the onset and progression of 
hypertension and associated cardiovascular pathology.92 The ROS family consists of 
many molecules that have varied effects on growth, differentiation, modulation and 
breakdown of extracellular matrix, inactivation of antioxidant defense system, and 
initiation and maintenance of pro-inflammatory cascades.93-95 Xanthine oxidase, 
uncoupling of NO and tetrahydrobiopterin (BH4), and NADPH oxidase are the 
important sources of ROS in vascular disease, of which NADPH oxidase derived ROS 
plays a major role in Ang II-induced hypertension.16,96-98 The prototypic NADPH oxidase 
has three cytosolic subunits (p47 phox, p67 phox, p40phox) and two membrane subunits 
(p22 phox and the catalytic subunit gp91 phox) that occur as a heterodimeric 
flavoprotein: cytochrome b558.99,100 On stimulation, p47 phox undergoes 
phosphorylation, and the cytosolic subunits assemble to form a complex and translocate 
to the membrane where it associates with cytochrome b558 to form the active oxidase. 
The NADPH oxidase comprises seven members: NOX 1, 2, 3, 4, and 5 and Duox 1, and 
2.  
 
Many models of hypertension have demonstrated the link between oxidative 
stress and increased BP. It has been shown that in SHRs, increased ROS formation 
precedes development of hypertension thus implying that ROS is important for the 
development and maintenance of hypertension.101,102 Also in experimental hypertension, 
several markers of oxidative stress, such as thiobarbituric acid reactive substances 
(TBARS) and F2-isoprostanes are increased.103-105 Many studies have also successfully 
demonstrated the involvement of specific subunits of NADPH oxidase in Ang II-induced 
hypertension. Ang II infusion failed to induce hypertension, vascular hypertrophy, and 
endothelial dysfunction in p47 phox and gp91 phox knockout mice compared to their WT 
counterparts.98,106,107 Another study showed that mice treated with (short interfering 
RNA) siRNA against renal p22 phox demonstrated blunted hypertension and reduced 
ROS formation, implying that p22 phox is essential for Ang II-induced hypertension,108 
however, its overexpression did not significantly increase BP but did result in increased 
oxidative stress and endothelial dysfunction.109 Pharmacological inhibition of NADPH 
oxidase with apocynin, reduced vascular O2 production, prevented cardiovascular 
remodeling and attenuated Ang II-induced hypertension.97  
 
 
2.2.5 Nitric Oxide 
 
Many studies have established that NO-induced arterial vasodilation is impaired 
in various models of hypertension110,111 and NO bioavailability plays a major role in 
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endothelial dysfunction.112 NO is produced in the vascular endothelin from L-arginine by 
endothelial nitric oxide synthase (eNOS). eNOS null mice and inhibition of eNOS by L-
NAME exhibit severe hypertension,113,114 and administration of L-arginine and BH4,a 
cofactor of eNOS, have demonstrated a reduction in BP and improvement in 
endothelial function in both animal models and patients.115-118 Nebivolol, a NO 
releasing β blocker improves endothelial function by increasing NO bioavailability 
not through its β blocking ability.119 The most important cause for decreased 
bioavailability of NO is ROS.120 Hypertension, smoking, obesity, and dyslipidemia, 
disrupt antioxidant defense mechanisms, such as NO bioactivity, thus resulting in 
oxidation of biomolecules that leads to vascular inflammation, and development of 
atherosclerosis and cardiovascular diseases.120 A balance between NO bioavailability 
and ROS production must at least be maintained if not favored towards NO. A tilt 
towards ROS may lead to decreased endothelium-dependent vasodilation, thus 
resulting in, or further exacerbating, hypertension.121,122 Many studies have shown that 
Ang II decreases NO bioavailability by promoting production of ROS123 and 
superoxide dismutase, and antioxidants such as vitamin C restore endothelial function 
in both humans and animal models.124,125 
 
 
2.2.6 Eicosanoids 
 
Eicosanoids (Figure 2.3) generated from AA, released from tissue phospholipids 
by the action of one or more phospholipases, mainly PLA2. AA is metabolized by 
cyclooxygenase, lipoxygenase and cytochrome P450 monooxygenase into various 
vasoactive eicosanoids. These eicosanoids exert pro-hypertensive as well as anti-
hypertensive effects.126-130  
 
 
2.2.6.1 Cyclooxygenase Derived Eicosanoids 
 
There are at least two forms of COX enzymes: COX-1, the constitutively active 
form and COX-2 the inducible form. COX catalyzes the metabolism of AA into 
prostaglandin (PG) H2, which by the action of prostacyclin synthase is further converted 
to PGI2 (prostacyclin), E2, D2, and F2α. PGH2 is also metabolized by thromboxane (Tx) 
A2 synthase to TxA2. 
 
PGE2 and I2 are known to exert anti-hypertensive effects by dilating resistance 
vessels, reducing release of norepinephrine (NE), attenuating response to 
vasoconstrictors, and promoting salt and water excretion.131 Treatment with COX 
inhibitors results in decreased production of PGE2 and I2, leading to increased vascular 
resistance, responsiveness to vasoconstrictors including Ang II, and suppression of 
pressure natriuresis response,132,133 thereby resulting in increased BP and renal 
dysfunction to a greater extent in hypertensive than normotensive states.134 Also, it has 
been shown that rats infused with Ang II show an increase in plasma concentration of 
derivative of PGI2; 6-keto-PGF1α.135 The general consensus is that PGE2 and I2  
 13 
 
 
Figure 2.3 Arachidonic acid metabolism 
 
Agonist (Ang II) induced (1) influx of Ca2+ (2) results in translocation of cPLA2α from 
cytosol to nuclear envelope (golgi, ER) (3) and undergoes phosphorylation (4) which 
increases its hydrolytic activity that results in AA release (5) from tissue phospholipids. 
AA is metabolized by cytochrome P450, cyclooxygenase and lipoxygenase to various pro 
and anti-hypertensive eicosanoids. 
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contribute to anti-hypertensive mechanisms however, this view is somewhat 
controversial. These eicosanoids are also known to stimulate renin secretion,136 and, in 
some studies, treatment with Cox inhibitors has been shown to lower BP and reduce 
plasma renin activity.137 Also it has been demonstrated that PGH2, is a mediator of 
endothelium dependent vasoconstriction in arteries of hypertensive animals.138 TXA2, a 
powerful vasoconstrictor, is known to serve pro-hypertensive effects, and both TXA2 and 
PGH2 receptors may function in concert to stimulate contraction of VSMC, produce renal 
vasoconstriction and reduce renal blood flow.127 It has been demonstrated that infusion of 
TXA2/PGH2 receptor agonist results in BP elevation,139 while inhibition of  thromboxane 
synthase lowers BP in certain models of experimental hypertension.140,141 
 
 
 2.2.6.2 Lipoxygenase Derived Eicosanoids 
 
Lipoxygenases (LOX) are a group of non-heme iron containing dioxygenases142 
that metabolize AA into 5,- 12,- 15- hydroxyeicosatetraenoic acids (HETE) and different 
forms of leukotrienes (LT).143 Many studies have demonstrated the role of 12-HETE in 
BP regulation. Some studies suggest its role as an anti-hypertensive eicosanoid, while 
others refer it to as pro-hypertensive. 12-HETE has been shown to inhibit renin secretion 
in rat renal slices, and inhibition of LOX increases plasma renin activity in rats 
suggesting that 12-HETE could serve as a negative regulator of renin.144 However, many 
studies have also shown that 12- hydroperoxyeicosatetraenoic acid (HPETE) and 15-
HPETE (precursors of 12-and 15- HETEs) inhibit prostacyclin synthase,145,146 indicating 
its pro-hypertensive function. 12-HETE also mediates Ang II-induced afferent artery 
constriction in the kidney. Inhibition of LOX has also been shown to attenuate Ang II- 
induced vasoconstriction147 and to reduce BP in SHR.148 Moreover, Ang II has been 
shown to increase the protein, as well as mRNA expression, of 12-LOX in VSMC.149 In 
various models of hypertension including two-kidney one clip150 and aortic coarctation-
induced hypertension,145 an increase in the levels of HETEs has been observed. Thus, it 
appears that LOX derived eicosanoids serve a pro-hypertensive function.  
 
 
2.2.6.3 Cytochrome P450 Monooxygenase Derived Eicosanoids 
 
Until 1981, cytochrome P450s (Cyp 450) were recognized only as enzymes 
required for metabolism and detoxification of xenobiotics. The discovery of their role in 
the AA cascade opened new vistas, and the diverse nature and functions of the enzyme 
was identified. One of the earliest studies, by McGiff and his collaborators, demonstrated 
the contribution of renal CYP4A in the pathophysiology of hypertension.151,152 Cyp 450 
via its epoxygenases metabolizes AA into biologically active cis-epoxyeicosatrienoic 
(EET) acids; 5,6-, 8,9-, 11,12-, 14,15-EETs and via its ?-hydroxylase activity into 19- 
and 20-HETEs.153,154 Subsequent studies recognized EETs in the activation of calcium 
sensitive potassium channels, resulting in hyperpolarizing of membrane potential.155 
 
They play a major role in regulating vascular tone, ion transport, proliferation 
inflammation, and hemostasis.154,156-158 More recent studies have sketched an anti-
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hypertensive image of EETs. Overexpression of P450 epoxygenases or treatment with 
synthetic EETs resulted in upregulation of eNOS via activation of MAPK and PKC 
signaling pathways.159 In another long term study, overexpression of CYP2J2 using a 
type 8 recombinant adeno-associated virus vector in SHR increased urinary expression of 
14,15 EETs, enhanced mRNA expression of atrial natriuretic peptide, decreased BP, and 
improved cardiac output. Furthermore, when the specific inhibitor of CYP2J2 was 
administered, it blocked this hypotensive effect and attenuated the increase in the levels 
of EETs.160 Furthermore, Capdevila et al, demonstrated that Cyp2c44-/- mice on a high 
salt diet develop hypertension and exhibit increased epithelial sodium channel (ENaC) 
activity,161 thus implying the importance of Cyp2c44 in regulating BP by controlling 
ENaC activity.  
 
CYP4A metabolites of AA have been much appreciated as the anti-hypertensive, 
anti-inflammatory arm of the AA metabolism cascade; however, studies in our lab have 
demonstrated that the effect of Ang II on VSMC migration, proliferation, and 
hypertrophy is via AA release and its metabolism to ROS by CYP1B1.162 Moreover, 
male Cyp1b1−/− mice infused with Ang II13,14 or treated with deoxycorticosterone acetate 
(DOCA)/salt163 are protected against hypertension, endothelial dysfunction, cardiac 
hypertrophy, fibrosis, and inflammation. Also, treatment with the inhibitor of CYP1B1, 
2, 3′, 4, 5′-tetramethoxystilbene minimizes hypertension caused by Ang II in Cyp1b1+/+ 
mice.14,164 Moreover, ROS generated via the metabolism of AA by CYP 1B1, via second 
messenger systems, ERK1/2, p38 MAPK, and cSrc stimulate VSMC growth, and 
contribute to the development of hypertension and associated pathophysiology.162 
 
 AA metabolism is also associated with generation of ROS165 that have been 
implicated in hypertension.166 Therefore, the balance between pro- and anti-hypertensive 
eicosanoids and generation of ROS, would determine the level of BP. Whether AA 
metabolites generated via different pathways, following their release by activation of 
cPLA2 by Ang II, contribute primarily to pro- or antihypertensive mechanisms, is not 
known. 
 
 
2.2.7 Emerging Concepts of the Immune System in Hypertension 
 
One of the earliest reports demonstrated that lymph node cells from hypertensive 
rats, when introduced in normotensive rats, raised their BP.167 Later, it was shown that 
nude mice lacking a thymus or thymectomized mice did not exhibit hypertension 
following renal infarction.168 Another study demonstrated that SHR that received donor 
thymus from Wistar Kyoto rats showed a reduction in BP.169 
 
More recent studies have shown that mice lacking B and T cells (RAG-/-) are 
protected against Ang II-induced hypertension, endothelial dysfunction, and superoxide 
production compared to wild type (WT) mice, and adoptive transfer of T but not B cells 
restored hypertension.170 Ang II infusion in WT mice, resulted in an increase in 
circulating levels of CD69+, CCR5+, and CD44high, suggesting the involvement of T cells 
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in hypertension.170 Furthermore, Dahl salt sensitive rats deficient in RAG-1 demonstrated 
decreased BP, kidney damage, and albuminuria.171  
 
T cells have many subgroups, one of them being CD4+ T cells that include Th1, 
Th2, Th17, and T regulatory cells (Tregs).172 Interleukin (IL)-17A, a cytokine released by 
Th17 cells, has been implicated in the pathogenesis of many autoimmune and 
inflammatory diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis, asthma, 
inflammatory bowel disease, and periodontal disease.173,174 Recent studies have 
demonstrated the role of Th17 cells in Ang II-induced hypertension. IL-17-/- mice infused 
with Ang II demonstrated an initial increase in BP, which dropped after 7 days, and T cell 
infiltration that was observed in WT mice was abolished in IL-17-/- mice. Ang II 
increased IL-17 protein deposition in the aortic wall of WT mice.175 The involvement of 
other cytokines has also been reported. Marko et al, demonstrated that interferon (IFN)-γ 
receptor knockout mice are protected against Ang II-induced cardiac hypertrophy, 
macrophage and T-cell infiltration, fibrosis, and arrhythmogenic electric remodeling 
compared to WT mice. Also the researchers observed reduced renal inflammation, 
tubulointerstitial damage, and improved GFR.176 In another study, tumor necrosis factor 
(TNF)-α inhibitor etanercept reduced infiltration of inflammatory and immune cells in a 
model of Ang II-induced renal damage.177 Zhang et al. presented evidence in both human 
and mice demonstrating the role of cytokine IL-6 in Ang II induced hypertension. They 
reported a significant increase in IL-6 expression in kidney samples collected from 
chronic kidney disease patients with hypertension. They also showed that Ang II is 
responsible for IL-6 induction in murine studies and its genetic deletion significantly 
reduced hypertension, ET production, renal injury, and fibrosis.178  
 
Patients suffering from AIDS who have a low CD4+ T cell count, show a low 
incidence of hypertension, but when treated with aggressive antiretroviral therapy, 
develop increased SBP.179 Mycophenolate mofetil, a T-lymphocyte specific 
immunosuppressant used to treat psoriasis and rheumatoid arthritis, ameliorates 
hypertension in patients, thus suggesting the involvement of the immune system, more so 
the role of T cells in hypertension.180  
 
Based on these and other findings, Harrison et al, proposed a model of T cell 
mediated immunity in hypertension15 (Figure 2.4), which suggests that hypertensive 
triggers such as Ang II, catecholamines, stress, ROS, and a high salt diet via its actions on 
the circumventricular organs in the brain, may result in microglial activation, cytokine 
production, and increased sympathetic activity resulting in a small elevation in BP (pre 
hypertension) which may result in formation of neo antigens. These neo antigens may 
further promote T cell activation resulting in T cell infiltration in the vasculature and 
kidney, further causing severe hypertension. Thus the evidence presented above strongly 
implicates the involvement of the immune system in hypertension.  
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Figure 2.4 T cell mediated immunity in hypertension 
 
Reprinted with permission. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, 
Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. 
Hypertension. 2011;57:132-140.15  
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2.3 Cytosolic Phospholipase A2α 
 
 
2.3.1 Phospholipases: An Introduction 
 
More than 30 phospholipases that catalyze the hydrolysis of membrane 
glycerophospholipids at the sn-2 position, liberating AA, and lysophospholipids have 
been discovered so far.181 Based on the evolutionary relationship, structure, function, and 
catalytic activity, PLA2 has been classified into sPLA2, cPLA2, iPLA2 also called patatin 
like phospholipase domain-containing lipases, and platelet activating factor 
acetylhydrolase.2 Hereafter, I shall focus on the role, significance, and function of 
cPLA2? in hypertension. Of all the phospholipases, cPLA2? specifically catalyzes the 
hydrolysis of phospholipids containing AA.182  
 
 
2.3.2 Structure 
 
Group IV cytosolic phospholipase A2, an 85 KDa molecule, was first identified in 
human platelets in 1986.183 The structure (Figure 2.5) of the enzyme consists of a C2 
domain at the N-terminal, composed of eight antiparallel β strands interconnected by six 
loops. It contains the Ca2+ binding motif followed by the catalytic domain composed of 
14β strands and 13α helices and houses the α/β hydrolase segment, which is conserved 
across many lipases.184 Unique to cPLA2α, within the hydrolase segment, lies, the novel 
cap region, which also has a lid region. The C2 domain has two Ca2+ binding sites and is 
required for its membrane translocation from cytosol to membrane in response to Ca2+ 
signaling, whereas the catalytic domain contains crucial sites of phosphorylation 185 and 
is required for the stable binding of the enzyme to the membrane after [Ca2+]i 
decreases.186 
 
 
2.3.3 Regulation 
 
AA release via the hydrolytic activity of cPLA2α is mediated by two very 
important post translation mechanisms: being: increase in [Ca2+]i and 
phosphorylation.187,188 During agonist-induced [Ca2+]i increase, two Ca2+ ions bind to 
calcium binding loops in the C2 domain.189-192 The electrostatic potential of the surface 
exposed calcium binding loops is reduced, this facilitates the penetration of the 
hydrophobic residues into the Golgi membrane.193,194 The basic residues in the C2 
domain bind to ceramide 1 phosphate, and the catalytic domain positions itself on the 
phospholipid membrane, and Ser505on the catalytic domain is phosphorylated by MAPK, 
resulting in increased hydrolytic activity of the enzyme. The basic residues in the 
catalytic domain bind to phosphatidylinositol 4,5-bisphosphate and stimulate the ability 
of the enzyme to release AA.  
 
Both the amplitude and duration of [Ca2+]i are important determinants for 
translocation and regulation of cPLA2α activity.195 The initial transient release of Ca2+  
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Figure 2.5 Structure of cPLA2α 
 
Reprinted with permission. Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. 
Phospholipase A2 enzymes: physical structure, biological function, disease implication, 
chemical inhibition, and therapeutic intervention. Chemical reviews. Oct 12 
2011;111(10):6130-6185.196   
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from intracellular stores is important for immediate translocation of cPLA2α to Golgi;197 
however, the subsequent influx of Ca2+ is required for maintaining the stable binding of 
the enzyme to Golgi to release AA.197 The hydrolytic activity of the enzyme is tightly 
regulated by phosphorylation (Figure 2.6). Of the three phosphorylation sites, Ser505 is 
the best studied. Phosphorylation of Ser505 is not sufficient for the release of AA, but is 
important as it enhances membrane binding affinity even at low Ca2+ levels198 and 
facilitates AA release. The main function of Ser505 phosphorylation is to induce a 
conformation change in the enzyme and to facilitate penetration of the hydrophobic 
residues in the active site, even at submicromolar levels of Ca2+.198 Studies have shown 
that phosphorylation of Ser505 depends on phosphorylation of Ser515 by CamKII.199 
Activation of cPLA2α by CaMKII results in generation of AA metabolites, particularly 
HETEs, which in turn by activating ERK1/2, phosphorylates cPLA2α at Ser505 thereby 
releasing further AA.200 Another important site of cPLA2α phosphorylation is Ser727 by 
MAPK-activated protein kinase.5 It is also a site for binding of the p11anexin, an 
inhibitory complex that prevents binding of the enzyme to the Golgi. Phosphorylation of 
Ser727 disrupts this interaction and allows enzyme activation.201 
 
 
2.3.4 cPLA2α in Disease Pathogenesis : Lessons from the Knockout Mouse 
 
cPLA2? has been implicated in the pathogenesis of various inflammatory diseases. 
Studies on cPLA2α-/- mice have revealed that stimulus induced production of 
prostaglandins and leukotrienes are greatly reduced in inflammatory and non-
inflammatory cells obtained from these mice.202-205 In an acute respiratory distress 
syndrome model, it has been shown that pulmonary edema, neutrophil sequestration and 
pulmonary fibrosis are markedly attenuated in cPLA2α-/- mice, and inhibition of cPLA2α 
may be the key in treating various pulmonary disorders.206,207 cPLA2α has also been 
implicated in multiple sclerosis, an autoimmune, inflammatory demyelinating disease 
resulting in motor and sensory defects. Multiple Sclerosis is thought to be mediated by 
the Th1/Th17 axis, in which several lipid mediators: PGE2, LTB4 and PAF are 
involved.208-212 cPLA2α-/- mice have been shown to be less susceptible than WT mice to 
experimental autoimmune encephalomyelitis disease model (animal model for multiple 
sclerosis), and pharmacological inhibition of cPLA2α blocked its onset and 
progression.213 Myelin oligodendrocyte glycoprotein specific T cells from the knockout 
mice revealed that loss of cPLA2α results in deficient production of Th1 cytokines, and 
administration of IL-12 (Th1 cytokine) once again makes the mice more susceptible to 
the disease, thus suggesting that cPLA2α facilitates the differentiation of T cells towards 
Th1 and Th17 phenotypes in autoimmune diseases. PGE2, PGI2 and LTB4 are involved 
in collagen-induced arthritis, which is also Th17 dependent; the incidence and severity of 
the disease are greatly reduced in cPLA2α-/- mice.214. Also, in a study of post ischemic 
brain injury, it was observed that cPLA2α-/- mice had smaller infarcts, less brain edema 
and fewer neurological deficits after transient middle cerebral artery occlusion.204. In a 
more recent study, Saito et al, demonstrated that disruption of cPLA2α attenuates 
myocardial ischemia/reperfusion injury compared to its WT counterparts, partly through 
inhibition of TNF-α-mediated pathways.215 Tanaka et al, showed the involvement of  
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Figure 2.6 Phosphorylation sites of cPLA2α 
 
Reprinted with permission. Linkous A, Yazlovitskaya E. Cytosolic phospholipase A2 as a 
mediator of disease pathogenesis. Cell Microbiol. 2010;12(10):1369-1377.7 
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endothelial cPLA2α in L-NAME-induced hypertension.9 All the above findings suggest 
the interplay of cPLA2 with the immune system in various disease pathologies. cPLA2  
seems to act as a catalyst in disease pathogenesis and progression; thus, cPLA2 inhibition 
may be the key in treating hypertension, which is now being recognized as an immune 
system driven disease as discussed above.  
 
Therefore, based on the above review of the literature, it is possible that cPLA2α, 
which is highly selective in releasing AA, might function as the major center of 
convergence for the transduction of Ang II signaling to produce pro-hypertensive 
eicosanoids and ROS. These would, in turn, result in development of hypertension and 
associated cardiovascular and renal dysfunction and pathophysiological changes 
including activation of immune system, inflammation, and end organ damage. Thus, this 
central hypothesis is the major objective of my thesis, to test this hypothesis; I have 
investigated the effect of cPLA2? gene disruption in mice on Ang II-induced 
hypertension and associated cardiovascular and renal function and pathogenesis. 
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CHAPTER 3.    METHODOLOGY 
 
 
3.1 Animals 
 
Experiments were performed according to protocols approved by our Institutional 
Animal Care and Use Committee in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. cPLA2α-/- mice on a BALB/c 
background were generated as described204 and provided by Dr. Joseph V. Bonventre at 
Brigham and Women's Hospital, Boston, MA. Homozygotes (cPLA2α-/-) were interbred 
in our facility, and their genotypes were regularly confirmed by polymerase chain 
reaction analysis. WT male BALB/c mice (cPLA2α+/+) used in this study were purchased 
from Charles River Laboratories, Inc., Wilmington, MA. All animals were 20-30 g and 
approximately 10 weeks of age at the beginning of the experiment. 
 
 
3.2 Ang II-Induced Hypertension in cPLA2α+/+and cPLA2α -/- Mice 
 
Mice were anesthetized with 1.5% isofluorane to implant micro-osmotic pumps 
(Alzet®, Cupertino, CA; model 1002) subcutaneously to infuse Ang II (700 ng/kg/min) 
or vehicle (0.9% saline) for 2 weeks, and BP was measured once a week by the 
noninvasive tail cuff method (Kent Scientific, Torrington, CT; model XBP 1000). Prior 
to implanting the pumps, mice were acclimated twice to the BP measuring device, with 5 
days between measurements. These measurements were also confirmed by instrumenting 
the mice with a radio telemetry device (TPA-C10, Data Sciences International, St. Paul, 
Minnesota) as described previously.216 BP was recorded every third day. In another 
series, cPLA2α+/+ mice were infused with Ang II and injected i.p. with inhibitor of AA 
metabolism, 5,8,11,14-eicosatetraynoic acid (ETYA) (50 mg/kg/3day) (BML-ET004-
0020, Enzo Lifesciences, NY). At the end of the experiment, the mice were euthanized 
with a cocktail of ketamine (100 mg/kg), xylazine (10mg/kg), and acepromazine 
(3mg/kg) i.p., and their tissues were harvested. 
 
 
3.3 Ultra Sound Imaging and Analysis 
 
 
3.3.1 Echocardiography 
  
On the 12th day of the study, mice were anesthetized with 1.5% isoflurane, core 
body temperature was maintained at 37°C, and heart rate and respiration were 
continuously monitored with a pulse oximeter. Echocardiography was performed as 
described217 by using the Vevo 2100 (VisualSonics, Inc., Toronto, Canada). Briefly, M-
mode and B-mode images in the parasternal long-axis and the left ventricular (LV) short-
axis views at the mid papillary level were taken. Measurements were averaged from three 
consecutive beats. M-mode images were used to calculate various parameters of cardiac 
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function including ejection fraction (EF), fractional shortening (FS), stroke volume (SV), 
cardiac output (CO), and LV mass.  
 
 
3.3.2 Pulsed Wave Doppler to Measure Renal Hemodynamics 
 
On the 12th day of the study, mice were anesthetized with 1.5% isoflurane, core 
body temperature was maintained at 37°C, heart rate and respiration was continuously 
monitored with pulse oximeter. Imaging was performed using the Vevo 2100 
(VisualSonics Inc Toronto, Canada). Briefly, mice were placed on the platform in supine 
position. Long axis of the micro scan transducer was placed on the lateral side, aligned 
perpendicular to the long axis of the animal. M-mode and B-mode images were taken. 
The Right Renal Artery Peak Systolic Velocity (RRA PSV), Right Renal Artery Lowest 
Diastolic Velocity (RRA LDV), Right Renal Artery Velocity Time Integral (RRA VTI) 
were measured to calculate :- 
 
Renal Artery Pulsatility Index: (RRA PSV-RRA LDV)/RRA VTI, mean velocity 
 
Renal Artery Resistive Index: (RRA PSV-RRA LDV)/RRA PSV. 
 
Measurements were averaged from 3 consecutive waveforms.  
 
 
3.4 Immunohistochemistry 
 
Immunohistochemical analysis for α-smooth muscle actin (SMA) and 
transforming growth factor β (TGF-β) was performed to determine the extent of 
interstitial fibrosis as previously described.218 Also, tissue sections were processed for 
infiltration of CD3+ T cell and F4/80+ monocyte/macrophage. The hearts, thoracic aortas 
and kidneys were dissected free and placed in Optimal Cutting Temperature (OCT) 
compound (Sakura Finetek USA, Inc., Torrance, CA). Serial transverse cryosections (8-
μm thick) were cut at -20°C with a Leica Cryostat CM1850 (Leica Microsystems, Inc., 
IL). For α-SMA and TGF-β staining, sections were fixed in formalin for 10 min followed 
by three washes in PBS to remove the mounting medium, after which they were allowed 
to incubate in 0.3% hydrogen peroxide for 10 min to block endogenous peroxidase 
activity. The sections were then rinsed once in PBS and blocked in 5% BSA for 30 min. 
Sections were incubated with their respective primary antibodies overnight at 4?C. All 
antibodies were diluted in background reducing diluent (Cat #S3022, Dako, CA). Next 
day, sections were washed three times in PBS and incubated with anti-mouse IgG 
peroxidase-conjugated secondary antibody for 1 h, washed three times in PBS, and 
incubated in diaminobenzidine (Cat #D4293, Sigma Aldrich) that was prepared according 
to manufacturer’s instructions, and the tissue sections were then washed with deionized 
distilled water (ddw). For staining CD3+ and F4/80+ cells, tissue sections were fixed in 
cold acetone after which they were allowed to air dry 5-10 min to facilitate complete 
removal of acetone (sections should appear opaque white). Sections were then washed, 
followed by the steps described above (Table 3.1 contains detailed conditions). All
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Table 3.1. List of antibodies and specific conditions 
 
Antibody Application Primary Antibody Blocking Buffer Secondary Antibody 
Cat # Dilution Host Cat # Dilution 
α-SMA IHC Sigma A2547 1:400 Mouse 5% BSA A3682  1:150 
TGF-β IHC Santa Cruz sc-146 1:400 Rabbit Goat normal serum Vectastain ABC kit PK6101 - 
CD3 IHC Abcam ab5690 1:100 Rabbit 5% BSA Abcam ab97051 1:100 
F4/80 IHC AbDSerotec  MCA497R 1:50 Rat Rabbit normal serum AbD Serotec STAR72  1:50 
PLCβ WB Santa Cruz sc-205 1:500 Rabbit 5% BSA ECL Rabbit IgG NA934V 1:2000 
PLD1 WB Gift ** 1:500 Rabbit 5% BSA ECL Rabbit IgG NA934V 1:1000 
PLD2 WB Gift** 1:500 Rabbit 5% BSA ECL Rabbit IgG NA934V 1:1000 
AT1 WB Santa Cruz sc-1173 1:500 Rabbit 5% BSA ECL Rabbit IgG NA934V 1:1000 
AT2 WB Santa Cruz sc-9040 1:1000 Rabbit 5% BSA ECL Rabbit IgG NA934V 1:1000 
MAS WB Santa Cruz sc-135063 1:500 Rabbit 5% BSA ECL Rabbit IgG NA934V 1:1000 
ACE WB Santa Cruz sc-23908 1:500 Mouse 5% BSA ECL Mouse IgG NA931 1:1000 
P-cPLA2 WB Cell Signaling cs-2831 1:1000 Rabbit 5% BSA ECL Rabbit IgG NA934V 1:2000 
cPLA2 WB Santa Cruz sc-454 1:1000 Mouse 5% BSA ECL Mouse IgG NA931  1:2000 
P-ERK1/2 WB Cell Signaling cs-9106 1:1000 Mouse 5% BSA ECL Mouse IgG NA931 1:2000 
ERK1/2 WB Cell Signaling cs-9102 1:1000 Rabbit 5% BSA ECL Rabbit IgG NA934V 1:2000 
P-Src WB Cell Signaling cs-2101 1:1000 Rabbit 5% BSA ECL Rabbit IgG NA934V 1:2000 
c-Src WB Santa Cruz sc-8056 1:1000 Mouse 5% BSA ECL Mouse IgG NA931 1:2000 
β-actin  WB Santa Cruz sc-47778 1:10000 Mouse 5% BSA ECL Mouse IgG NA931 1:2000 
 
** Dr. Sylvain G. Bourgoin, Centre Hospitalier de l'Université Laval, Québec, Canada 
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sections were counterstained with hematoxylin, dehydrated, mounted, and viewed with 
an Olympus® inverted system microscope (Olympus America, Inc., model BX41) and 
photographed with a SPOT™ Insight™ digital camera (Diagnostic Instruments, Inc., 
model Insight 2MP Firewire). 
 
 
3.5 Collagen Accumulation  
 
Masson’s trichrome staining (Cat #HT15-1KT, Sigma Aldrich) for collagen 
accumulation was performed on the heart, aorta and kidney sections according to 
manufacturer’s instructions with some modifications. Briefly, slides were prefixed in 
10% formalin for 20 min followed by fixation in Bouin’s reagent overnight at room 
temperature. Next day, slides were washed in running tap water to drain the yellow stain 
from Bouin’s reagent completely followed by washing in ddw. Weigert’s iron 
hematoxylin solution (Cat# HT1079, Sigma Aldrich) was prepared according to vendor’s 
instructions and applied on the sections for 5 min, and excess stain was removed by 
rinsing under tap water followed by rinsing with ddw. Slides were then incubated with 
scarlet-fuschin for 5 min, then washed again with tap water followed by washing in ddw. 
1:1:2 volume of phosphotungstic acid, phosphomolybdic acid, and ddw was applied on 
the slide for 10 min. The solution from the slides was drained on a paper towel and then 
incubated with analine blue for 7 min, then washed with ddw. Tissue sections were then 
differentiated in 1% glacial acetic acid for 30 sec and then washed twice in ddw followed 
by dehydration in increasing strengths of alcohol and clearing in xylene after which slides 
were mounted using permount.  
 
 
3.6 Measurement of Oxidative Stress 
 
 
3.6.1 Measurement of NADPH Oxidase Activity 
 
NADPH oxidase activity was determined in heart homogenates by measuring 
lucigenin (N,N′-dimethyl-9,9′-biacridinium dinitrate)-enhanced chemiluminescence, as 
described previously,219 with some modifications. Following anesthesia, a transcardial 
PBS perfusion was performed; hearts and kidneys were harvested and snap-frozen in 
liquid N2 and stored at -80°C until use. Tissues were homogenized and sonicated in lysis 
buffer containing protease inhibitors (20 mmol/L phosphate buffer, 1 mmol/L EGTA, 10 
μg/ml aprotinin, 0.5 μg/ml leupeptin, 0.7 μg/ml pepstatin, 0.5 mmol/L 
phenylmethylsulphonylfluoride, and 150 mmol/L sucrose). Samples were then 
centrifuged at 3,000 g for 10 min at 4°C, and supernatants were kept on ice until use. 
Protein content in the samples was determined by the Bradford method, and equal 
amounts of protein were combined 1:1 with a reaction mixture containing 5 μmol/L 
lucigenin (final concentration) and 100 μmol/L NADPH (final concentration). 
Luminescence was measured every minute for 10 min with a luminometer (Turner 
Designs, Sunny Vale, CA; model TD-20/20). Lysis buffer was used as a blank and 
subtracted from each reading and activity expressed as arbitrary units. 
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3.6.2 Measurement of Urinary TBARS 
 
Levels of TBARS, byproduct of lipid peroxidation in the urine were measured 
using TBARS assay kit (Cayman cat # 10009055) as per manufacturer’s instructions. 
 
 
3.6.3 Measurement of ROS Production 
 
To measure ROS productions, sections of thoracic aortae, hearts and kidneys were 
exposed to DHE (Cat #D-2310, Life Technologies, NY) following the previously 
described and validated method.220 Aortic sections were incubated in PBS for 30 min at 
37°C and then encircled with a hydrophobic pen. DHE (2 μM for aorta, 5 μM for heart 
and kidney) was topically applied. Sections were further incubated at 37°C in a light-
protected humidified chamber for 30 min. Sections were then rinsed in PBS, and 
fluorescence was detected with a 585-nm filter and an Olympus® inverted system 
microscope (Olympus America, Inc.; model DP71). Superoxide production, was 
measured as fluorescence intensity of 2-Hydoxyethiduim (OHE). Images were 
photographed with an Olympus® digital camera (Olympus America, Inc., model DP71) 
and analyzed using ImageJ 1.42 (http://rsb.info.nih.gov/nih-image; National Institutes of 
Health). 
 
 
3.7 Analysis of Vascular Function 
 
 
3.7.1 Vascular Reactivity 
 
 Following anesthesia, the thoracic aortas were quickly dissected free and cleaned 
of surrounding tissue, and approximately 2-mm rings were mounted in a wire myograph 
system (Danish Myo Technology, Aarhus, Denmark; model 610M) as previously 
described.14 Vessels were continuously bathed in Krebs buffer (composition in mmol/L: 
118 NaCl, 4.7 KCl, 25 NaHCO3, 1.2 MgSO4, 1.2 KH2PO4, 11.1 glucose, 2.5 
CaCl2.2H2O) at 37°C, which was gassed with 95% O2 and 5% CO2 to maintain pH 7.4. 
An initial tension of 9 mN was placed on the vessels and allowed to equilibrate for 
approximately 30 min. To confirm the viability of the vessels, they were initially tested 
for constriction to 60 mM KCl and then washed three times with fresh Krebs buffer. 
Cumulative concentration response curves to phenylephrine (PE) and ET-1 were obtained 
and responses measured as force of contraction (mN). 
 
 
3.7.2 Endothelium-Dependent and Independent Vasodilation 
  
Endothelial function was examined14 by constricting the vessels with the 
concentration of PE that evoked a maximal response followed by adding increasing 
concentrations of acetylcholine (ACh). Changes in the response of vessels to ACh were 
measured and presented as a percentage of the PE-induced constriction. Endothelium-
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independent vasodilation was studied by constricting the vessels with the concentration 
of PE that evoked a maximal response followed by adding increasing concentrations of 
sodium nitroprusside (SNP). Changes in the response of vessels to SNP were measured 
and presented as a percentage of the PE-induced constriction. 
 
 
3.8 Assessment of Vascular Remodelling 
 
Aortic sections were stained with hematoxylin and eosin and viewed using an 
Olympus® inverted system microscope (Olympus America, Inc., Melville, NY; model 
IX50) and photographed with an Olympus® digital camera (Olympus America,Inc.; 
model DP71). Images were analyzed using ImageJ 1.42 (http://rsb.info.nih.gov/nih-
image; National Institutes of Health). 
 
 
3.9 Western Blot Analysis 
 
Heart and kidney samples were homogenized in lysis buffer, and protein content 
was determined by the Bradford method. 50 μg of proteins were loaded and resolved on 
8% or 12% SDS-polyacrylamide gels and processed for western blot analysis as 
described.221 Blots were probed with different primary and corresponding secondary 
antibodies (Table 3.1) Intensity of the bands was measured with ImageJ 1.42 software. 
 
 
3.10 Real-Time PCR Analysis 
 
Total RNA was extracted from the hearts with TRIzol reagent (Invitrogen, Grand 
Islands, NY) according to the manufacturer’s protocol. 1μg of purified RNA was reverse 
transcribed using SuperScriptTM III First Strand synthesis system (Invitrogen). 
Transcription level was normalized to cyclophilin D. Primers were designed (Table 3.2). 
The values were calculated by 2-ΔΔCt method.222 
 
 
3.11 Analysis of Renal Function 
 
Mice were individually housed in tecniplast metabolic cages. They were allowed 
to acclimate to the cages for 24 hrs on day 11 of the experiment. On day 13, urine was 
collected and its volume was measured along with food and water intake. Renal function 
including urine output, osmolality using a Vapro® vapor pressure osmometer (Wescor, 
South Logan, UT; model 5520), protein content by the standard Bradford method was 
determined as described previously. Serum ET was measured at our endocrinology core 
unit using an ELISA assay.  
 
 29 
Table 3.2. List of primer sequences 
 
Genes Forward Sequence Reverse Sequence 
cPLA2α GGG CCA TGG TGG GAT TC TAC CAT GTG GAT CCA GAA AGA C 
CPLA2β CCT GAG TAC CTT TGA CTT TGG G CTT TGT CAG GAG GTC AGT GAA G 
CPLA2γ GGA TCC TTT GCA CTA CTT GGA G GTT GTG CTC TAG CTT TAG GGT C 
sPLA2α CAA AGG GAA GAA GCC CAA ATG AGG AAG TTG GAT GCC AAG AG 
PLC-β1 GGA GGT GGT TCA GTA CAT CAA G CCT GGG TTC TCT CTT TCT ATC TCC 
PLC-β2 ATA GCC TCT CCT GTT ATC CTC C CTT GTA CAC GGA TTC TGG GAA G 
PLC-β3 GAG AGG ATG AGG AGG AAG ATG AAG GAA GAG CTG AGG CAT GTA GTT G 
PLC-β4 GGA CAA GTG CTA GAA TGT TCC C GTT CTA GTG ATA CTC CTC ACT GGG 
PLD1 GGA AAG GAA TAT CAG GCT GGT C GAA ATA GAG AGG GAA CTG CAC C 
PLD2 CCT CCA GAG ACA CAA AGT CTT G CAC CTC TTG GAC CAT CGA TAA C 
p58IPK TGG AGT AAA TGC GGA TGT GG ACG GTC GCT CTC CTA TAG TAT G 
Xbp1 AAG AAA GCC CGG ATG AGC AGC GTG TTC TTA ACT CCT GG 
CHOP TGT TGA AGA TGA GCG GGT G AGG TTC TGC TTT CAG GTG TG 
GRP78 AGT TGA TAT TGG AGG TGG GC CAT TGA AGT AAG CTG GTA CAG TAA C 
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3.12 Urinary Levels of PGE2 Metabolite 
 
PGE2 is rapidly converted in vivo to its 13,14-dihydro-15-keto metabolite that 
further under goes degradation to PGA products, thus we measured the concentration of 
PGE2 metabolites (PGEM) using an Prostaglandin E Metabolite EIA ELISA kit (Cayman 
Cat# 514531) as per manufacturer’s instructions. 
 
 
3.13 Assessment of GFR 
 
 Plasma and urine creatinine levels were determined at the national mouse 
metabolic phenotyping center at Yale University. Creatinine clearance as a measure of 
GFR was calculated using the below formula and expressed as ul/min. 
 
Creatinine clearance = Urine Creatinine x Urine Volume 
                                     Plasma Creatinine x 24 x 60 
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CHAPTER 4.    RESULTS 
 
 
4.1 Aim 1. To Determine the Contribution of cPLA2α to Ang II-Induced  
Hypertension and Associated Cardiovascular Pathophysiology 
 
 
4.1.1 cPLA2α Gene Disruption Does Not Alter Expression of Other Phospholipase 
Enzymes 
 
To asses if cPLA2α gene disruption alters the expression of other related genes in 
the phospholipase family; mRNA expression of various phospholipase enzymes was 
determined by quantitative Real-time PCR. Total RNA was extracted from the hearts of 
both cPLA2α+/+ and cPLA2α-/- mice as described in the methods. mRNA expression of 
cPLA2α was absent but not of PLA2, PLC, PLD  in the cardiac tissue of cPLA2α-/- mice. 
(Figure 4.1A)   
 
PL-Cβ2, D1, D2 have been implicated in cardiovascular diseases. To asses if Ang 
II infusion and/or cPLA2α gene disruption altered their protein expression, western blot 
analysis was performed. cPLA2α gene disruption did not alter protein expression of these 
enzymes in the hearts of cPLA2α-/- mice. (Figure 4.1B) 
 
 
4.1.2 cPLA2α Contributes to the Development of Ang II-Induced Hypertension, 
Activation of Cardiac cPLA2 and Increased Excretion of PGE2 Metabolites  
 
Ang II infusion over a period of 13 days significantly increased SBP, measured by 
the tail cuff method (Figure 4.2A) and radio telemetry (Figure 4.2B) in cPLA2α+/+ but 
not cPLA2α-/- mice. cPLA2 activity measured by its phosphorylation, but not its protein 
expression, was significantly increased in the cardiac tissue of Ang II-infused cPLA2α+/+ 
mice; the expression of cPLA2 protein was absent in cPLA2α-/- mice. (Figure 4.2C, D) 
This increase in SBP and activity of cPLA2 correlated with increased urinary excretion of 
PGE2 metabolites in cPLA2α+/+ but not cPLA2α-/- mice. (Figure 4.2E) 
 
 
4.1.3 Inhibition of Arachidonic Acid Metabolism, Abrogated Ang II-Induced 
Hypertension in cPLA2α+/+ Mice 
  
 In order to confirm our hypothesis that AA metabolism via cPLA2α is crucial in 
development of hypertension, ETYA, a competitive inhibitor of AA metabolism was 
used. In a separate series of experiments, BP was recorded in 4 groups of cPLA2α+/+mice. 
Mice were infused with vehicle-saline, Ang II, vehicle-ETYA (i.p) and Ang II+ETYA for 
a period of 13 days. BP was recorded once every week. Ang II increased SBP and 
treatment with ETYA every third day abrogated Ang II-induced hypertension (Figure 
4.3). 
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Figure 4.1 cPLA2α gene disruption prevents expression of cPLA2α but not other 
related phospholipase enzymes 
 
Comparison of myocardial mRNA expression levels of various phospholipases between 
cPLA2α+/+ and cPLA2α−/− mice at baseline (A). Comparison of protein expression in the 
heart from both vehicle and Ang II-treated cPLA2α+/+ and cPLA2α−/− mice (B).  
*P< 0.05 cPLA2α+/+ vs. cPLA2α-/- (n = 4 for all experiments, and data are expressed as 
mean ± SEM) 
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Figure 4.2 cPLA2α contributes to the development of Ang II-induced 
hypertension, activation of cardiac cPLA2α and increased excretion of PGE2 
metabolites  
 
SBP measured by tail cuff (A) and radiotelemetry (B). cPLA2 activity measured by its 
phosphorylation by western blot analysis (C) in the cardiac tissue. Quantified data (D)  
PGE2 metabolite excretion in urine (D)*P< 0.05 cPLA2α+/+ Veh vs. cPLA2α+/+ Ang II, 
łP< 0.05 cPLA2α+/+ Veh vs. cPLA2α-/- Veh #P< 0.05 cPLA2α+/+ Ang II vs. cPLA2α-/- Ang 
II (n = 3-6) for all experiments, and data are expressed as mean ± SEM) 
 
 
  
 ł 
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Figure 4.3 Inhibition of arachidonic acid metabolism, abrogated Ang II-induced 
hypertension in cPLA2α+/+ mice 
 
*P< 0.05 vehicle vs. Ang II, #P< 0.05 Ang II vs. Ang II+ETYA. (n = 6 for all 
experiments; data are expressed as mean ± SEM).  
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4.1.4 cPLA2α Gene Disruption Attenuates Cardiac Dysfunction and Hypertrophy 
Associated with Ang II-Induced Hypertension  
 
Cardiac functional and structural changes were measured by echocardiography on 
the 12th day of infusion of Ang II or its vehicle. M-mode images of the left ventricle (LV) 
in the parasternal long-axis view demonstrated dilated cardiomyopathy as indicated by 
LV chamber enlargement and impaired contractility in Ang II-infused cPLA2α+/+ but not 
cPLA2α-/- mice (Figure 4.4). Various parameters, measured, (Table 4.1), revealed 
cardiac dysfunction including an increase in LV mass in Ang II-infused cPLA2α+/+ but 
not cPLA2α-/- mice.  
 
 
4.1.5 cPLA2α Gene Disruption Prevents Cardiac Interstitial Fibrosis 
 
 It is well established that hypertension, in both humans and animal models results 
in fibrosis in the cardiac, vascular and renal tissues. To determine the contribution of 
cPLA2α in Ang II-induced cardiac interstitial fibrosis, immunohistochemical analysis was 
performed on cardiac sections for α-smooth muscle actin and TGF-β. Masson’s trichrome 
staining was also performed on the heart sections to assess collagen accumulation. The 
heart sections of Ang II-infused cPLA2α+/+ but not cPLA2α-/- mice showed fibrosis as 
indicated by increased staining with intracardiac α-smooth muscle actin (Figure 4.5A), 
transforming growth factor (TGF)-β (Figure 4.5B), and collagen (Figure 4.5C). 
 
 
4.1.6 cPLA2α Gene Disruption Prevents Cardiac Inflammation 
 
Recent studies have demonstrated the role of immune system activation in various 
models of hypertension. To determine the contribution of cPLA2α to inflammation 
associated with Ang II-induced hypertension, immunohistochemistry was performed for 
F4/80+ macrophages, and CD3+ T-lymphocytes in the cardiac tissue of cPLA2α +/+ and 
cPLA2α-/- mice. Ang II caused infiltration of F4/80+ macrophages (Figure 4.6A) and 
CD3+ T cells (Figure 4.6B) in the hearts of cPLA2α+/+ but not cPLA2α-/- mice. 
 
 
4.1.7 cPLA2α Gene Disruption Protects Against Ang II-Induced Vascular 
Remodeling 
  
To assess vascular remodeling, aortas were stained with Hematoxylin and Eosin 
(Figure 4.7A) and media:lumen ratio was calculated (Figure 4.7B). The aortae were also 
stained for α-smooth muscle actin and collagen. Ang II increased media:lumen ratio 
(Figure 4.7B), α-smooth muscle actin muscle actin (Figure 4.7C, D) positive stained 
cells and collagen accumulation (Figure 4.7E, F) in aortas of cPLA2α+/+ mice compared 
to cPLA2α-/- mice. 
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Figure 4.4 cPLA2α gene disruption attenuates cardiac dysfunction and 
hypertrophy associated with Ang II-induced hypertension 
 
Echocardiograms of the left Ventricle obtained in M mode parasternal long axis view. 
Red dotted line indicates LVIDs and green dotted line indicates LVIDd. 
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Table 4.1. Paramaters of cardiac function 
 
  cPLA2α+/+   cPLA2α-/- 
Parameters Vehicle Ang II   Vehicle Ang II 
EF% 63.94 ± 1.0 40.66 ± 3.2* 63.47 ± 2.4 63.97 ± 1.3# 
FS% 34.19 ± 0.8 19.39 ± 1.9* 33.77 ± 1.7 34.17 ± 0.9# 
SV 39.78 ± 1.2 23.48 ± 1.6* 37.33 ± 2.8 36.60 ± 2.5# 
CO 16.35 ± 0.6 11.80 ± 1.1* 15.11 ± 0.7 16.84 ± 2.5# 
LV mass 83.07 ± 7.3 146.66 ± 6.2* 92.90 ± 2.9 107.56 ± 7.8# 
LVID-d 3.61 ± 0.2 4.31 ± 0.05* 3.60 ± 0.2 3.66 ± 0.1# 
LVID-s 2.33 ± 0.1 3.63 ± 0.1* 2.33 ± 0.2 2.37 ± 0.1# 
LVAW-s 1.24 ± 0.1 1.44 ± 0.2 1.31 ± 0.1 1.55 ± 0.1 
LVAW-d 1.10 ± 0.1 1.36 ± 0.1 0.97 ± 0.1 1.07 ± 0.1 
LVPW-s 0.95 ± 0.1 1.15 ± 0.01 1.22 ± 0.2 1.56 ± 0.1 
LVPW-d 0.68 ± 0.03 1.05 ± 0.04 0.85 ± 0.1 0.91 ± 0.04 
EDV 62.36 ± 1.8 75.78 ± 1.9* 57.63 ± 4.7 58.59 ± 4.3# 
ESV 21.39 ± 0.7 53.50 ± 3.5* 22.38 ± 2.9 21.97 ± 2.5# 
IVS-s 1.48 ± 0.02 1.44 ± 0.01 1.21 ± 0.1 1.65 ± 0.1 
IVS-d 0.98 ± 0.04 1.06 ± 0.02   0.86 ± 0.1 1.05 ± 0.1 
 
EF, ejection fraction; FS, fractional shortening; SV, stroke volume (ul); CO, cardiac 
output (ml/min); LV mass, left ventricular mass (mgs); LVID, LV internal dimension 
(mm); LVAW, LV anterior wall (mm); LVPW, LV posterior wall (mm); EDV, end 
diastolic volume (ul); ESV, End systolic volume; IVS, Intraventricular septum (mm). s, d 
indicate systole or diastole. 
 
The parameters listed in the table were measured using M-mode and B-mode images in 
the short and parasternal long-axis views as described in the methods.  
*P< 0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P< 0.05 cPLA2α+/+Ang II vs.  
cPLA2α-/- Ang II (n=4-6 for each group; data are expressed as mean ± SEM). 
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Figure 4.5 cPLA2α gene disruption prevents cardiac interstitial fibrosis 
 
Immunohistochemical staining of α-smooth muscle actin (A) and TGF-β (B), (indicators 
of interstitial fibrosis). Masson’s trichrome staining for collagen accumulation (intense 
blue staining) (C) (n=4 for each group) 
 
  
 39 
 
 
 
 
Figure 4.6 cPLA2α gene disruption prevents cardiac inflammation 
 
Immunohistochemical analysis for F4/80+ macrophages (A) and CD3+ T cells (B) in 
cardiac sections (n=4 for each group) 
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Figure 4.7 cPLA2α gene disruption protects against Ang II-induced vascular 
remodeling 
 
Sections of aortae were stained with hematoxylin and eosin (A), α-smooth muscle actin 
(C), and Masson’s trichrome for collagen (E). (B,D,F represent corresponding 
quantification of data)  
*P< 0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P< 0.05 cPLA2α+/+Ang II vs.  
cPLA2α-/-Ang II (n=3-5 for each group; data are expressed as mean ± SEM).  
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4.1.8 cPLA2α Gene Disruption Prevents Increased Vascular Reactivity and 
Endothelial Dysfunction in Ang II-Induced Hypertension 
 
Ang II-induced hypertension was associated with increased response of aorta to 
vasoconstrictors phenylephrine (Figure 4.8A) and endothelin-1 (Figure 4.8B) in 
cPLA2α+/+ mice; these increases were abrogated in cPLA2α-/- mice. Ang II-infusion 
caused endothelial dysfunction, as indicated by diminished dilation to ACh in aorta 
preconstricted with phenylephrine in cPLA2α+/+ but not cPLA2α-/- mice (Figure 4.8C). 
The endothelial-independent relaxation of aorta to SNP, that acts directly on vascular 
smooth muscle was not altered (Figure 4.8D).  
 
 
4.1.9 cPLA2α Gene Disruption Does Not Alter Expression of AT1, AT2, MAS 
Receptors and ACE 
 
To determine if decreased BP during Ang II-infusion in cPLA2α-/- mice is a result 
of alterations in expression of AT1, AT2, Ang (1-7) Mas receptor, or ACE, western blot 
analysis was performed to determine their protein expression in the cardiac tissue. 
Expression of AT1, AT2, Mas receptor, and ACE were not altered in any treatment 
groups (Figure 4.9).  
 
 
 4.1.10 cPLA2α Gene Disruption Protects Against Ang II-Induced Cardiovascular 
Oxidative Stress 
 
Oxidative stress has been implicated in various models of hypertension including 
Ang II16,166, and Ang II-induced activation of cardiac NADPH oxidase depends on PLA2 
activity in vascular smooth muscle cells in vitro.223,224 Therefore, we investigated whether 
cPLA2 gene disruption prevents Ang II-induced oxidative stress in heart and aorta. 
NADPH oxidase activity measured by lucigenin-based luminescence assay was increased 
in the hearts of Ang II-infused cPLA2α+/+ but not cPLA2α-/- mice (Figure 4.10A). 
Infusion of Ang II increased cardiac (Figure 4.10B, C) and aortic (Figure 4.10D, E) 
ROS production in cPLA2α+/+ but not in cPLA2α-/- mice measured by fluorescence of 2-
hydroxyethidium generated after exposure to DHE.  
 
 
4.1.11 cPLA2α Gene Disruption Prevents Endoplasmic Reticulum Stress in Ang II-
Induced Hypertension 
 
Endoplasmic reticulum (ER) stress has been implicated in Ang II-induced 
hypertension.225 To determine if Ang II-infusion promotes ER stress in the heart and if it 
is dependent on cPLA2α, we measured mRNA expression of ER stress biomarkers 
p58IPK, GRP78, XBP and CHOP. Ang II infusion increased cardiac mRNA expression of  
p58IPK that is induced in the early adaptive phase of the unfolded protein response, and 
CHOP (GADD153), a chronic ER stress marker226 in cPLA2α+/+ but not in cPLA2α-/- mice 
(Figure 4.11). 
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Figure 4.8  cPLA2α gene disruption prevents increased vascular reactivity and 
endothelial dysfunction in Ang II-induced hypertension 
  
The vascular response of aorta to increasing concentrations of PE (A) ET-1 (B) The 
vascular response to increasing concentrations of Ach (endothelium-dependent relaxation 
(C) and SNP (endothelium-independent relaxation) (D) was examined in the thoracic 
aorta from animals in each of the groups.  
*P< 0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P< 0.05 cPLA2α+/+Ang II vs.  
cPLA2α-/- Ang II (n = 5 for all experiments; data are expressed as mean ± SEM). 
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Figure 4.9 cPLA2α gene disruption does not alter expression of AT1, AT2, MAS 
receptors and ACE  
 
Western blot analysis was performed on the heart homogenates with respective 
antibodies. Protein expression of these receptors and ACE was not altered (n = 3 for all 
experiments) 
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Figure 4.10 cPLA2α gene disruption protects against Ang II-induced 
cardiovascular oxidative stress 
 
NADPH oxidase activity measured in kidney homogenate (A), ROS production 
determined by DHE staining in the heart (B,C) and aorta (D,E)quantified as fluorescence 
of 2-OHE 
*P<0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P<0.05 cPLA2α+/+Ang II vs. cPLA2α-/-
Ang II (n=5 for each group; data are expressed as mean ± SEM). 
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Figure 4.11 cPLA2α gene disruption prevents ER stress in Ang II-induced 
hypertension 
  
RT-PCR analysis was performed using cardiac mRNA for various ER stress biomarkers: 
p58IPK, GRP78, XBP, and CHOP. 
*P<0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P<0.05 cPLA2α+/+Ang II vs. cPLA2α-/-
Ang II (n = 4 for all experiments; data are expressed as mean ± SEM). 
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4.1.12 cPLA2α Gene Disruption Prevents Ang II-Induced Phosphorylation of 
ERK1/2 and c-Src  
 
It is well established that, in VSMC, Ang II increases the production of ROS, and 
activity of ERK1/2 and cSrc that contributes to hypertrophy.59 ERK1/2 also promotes 
phosphorylation of cPLA2.3 Ang II-infusion increased ERK1/2 (Figure 4.12A) and cSrc 
activity (Figure 4.12B) as measured by phosphorylation of these kinases in the heart 
tissue of cPLA2α+/+ but not in cPLA2α-/- mice.  
 
 
4.2 Aim 2. To Demonstrate that cPLA2α Is Essential in Ang II-Induced Renal 
Pathophysiology Associated with Hypertension 
 
 
4.2.1 cPLA2α Gene Disruption Prevents Against Ang II-Induced Altered Renal 
Hemodynamics 
 
Renal Doppler imaging was performed and renal artery resistive (Figure 4.13D) 
and pulsatility index (Figure 4.13E) were calculated as a measure of resistance and 
variability of blood velocity in the renal artery. These parameters are widely used to 
assess renal failure and extent of damage in humans. In the present study, Ang II infusion 
for 13 days increased renal vascular resistance and pulsatility index in cPLA2α+/+ but not 
in in cPLA2α-/- mice. 
 
 
4.2.2 cPLA2α Gene Disruption Prevents Ang II–Induced Renal Dysfunction  
 
Water intake and urine output were not different between cPLA2α+/+ and cPLA2α-/- 
mice. Infusion of Ang II for 13 days increased water intake (Figure 4.14A), urine output, 
(Figure 4.14B), decreased urine osmolality (Figure 4.14C), increased glomerular 
filtration rate as determined from creatinine clearance (Figure 4.14D), and caused 
proteinuria (Figure 4.14E) in cPLA2α+/+ but not cPLA2α-/- mice. 
 
 
4.2.3 cPLA2α Gene Disruption Prevents Renal Fibrosis in the Kidney 
 
Increased interstitial staining of α-SMA (Figure 4.15A) and TGF-β (Figure 
4.15B) indicators of interstitial fibrosis, was observed in renal sections from Ang II-
infused cPLA2α+/+ but not in cPLA2α-/- mice.  Masson’s trichrome staining revealed 
increased collagen accumulation (intense blue staining) (Figure 4.15C) in the interstitial 
space in Ang II-infused cPLA2α+/+ but not cPLA2α-/- mice.  
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Figure 4.12  cPLA2α gene disruption prevents Ang II-induced phosphorylation of 
ERK1/2 and cSrc 
 
Erk1/2 (A) and cSrc (B) activities were measured in heart homogenates by Western blot 
analysis as described in the methods (n = 3 for all experiments). 
*P<0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P<0.05 cPLA2α+/+Ang II vs. cPLA2α-/-
Ang II 
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Figure 4.13 cPLA2α gene disruption prevents against Ang II-induced altered renal 
hemodynamics 
 
Representative ultrasound B mode image of the kidney in transverse view (A) Color 
Doppler to visualize blood flow (B) Pulse wave Doppler mode (C) Renal artery resistive 
index (D) and renal artery pulsitality index (E) 
*P<0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P<0.05 cPLA2α+/+Ang II vs. cPLA2α-/-
Ang II (n = 4 for all experiments; data are expressed as mean ± SEM)   
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Figure 4.14 cPLA2α gene disruption prevents Ang II–induced renal dysfunction  
 
Water intake (A), urine output (B) measured on day 13 of Ang II infusion, urine 
osmolality (C), creatinine clearance (D) and protein excretion in the urine (E) was 
measured 
*P<0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P<0.05 cPLA2α+/+Ang II vs. cPLA2α-/- 
(n = 6-10 for all experiments; data are expressed as mean ± SEM) 
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Figure 4.15 cPLA2α gene disruption prevents renal fibrosis in the kidney 
 
Immunohistochemical analysis for α-SMA (A), TGF-β (B) and Masson’s trichrome 
staining for collagen (C) in renal sections. 
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4.2.4 cPLA2α Gene Disruption Prevents Renal Inflammation  
  
To determine the contribution of cPLA2α to inflammation associated with Ang II-
induced end organ damage, we examined the localization of CD3+ T-lymphocytes and 
F4/80+ macrophages in the renal tissue. Ang II infusion resulted in increased 
accumulation of CD3+ T cells in the interstitium (Figure 4.16A) and glomerulus (Figure 
4.16B) and infiltration of F4/80+ macrophages (Figure 4.16C) in the renal interstitium of 
cPLA2α +/+ but not cPLA2α-/- mice  
 
 
4.2.5 cPLA2α Gene Disruption Protects Against Ang II-Induced Renal Oxidative 
Stress 
 
Infusion of Ang II for 13 days increased renal NADPH oxidase activity (Figure 
4.17A) and urinary TBARS (Figure 4.17B), a byproduct of lipid peroxidation in 
cPLA2α+/+ but not in cPLA2α-/- mice. This data correlated with increased superoxide 
production in renal sections of cPLA2α+/+ mice, as indicated by 2-OHE fluorescence 
intensity (Figure 4.17C, D). This increase was not observed in cPLA2α-/- mice infused 
with Ang II 
 
 
4.2.6 Protection Against Ang II-Induced Hypertension in cPLA2α-/- Mice Is 
Independent of Endothelin 
 
Ang II infusion increased endothelin levels (Figure 4.18) to the same extent in 
both cPLA2α+/+ and cPLA2α-/- mice, however this did not reach significant difference 
demonstrating that reduced SBP in cPLA2α-/- mice after Ang II infusion is independent of 
endothelin.  
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Figure 4.16 cPLA2α gene disruption prevents renal inflammation  
 
CD3+ T cell staining in the interstitium (A) and glomerulus (B) and F4/80+ macrophages 
in the interstitium (C) of the kidney. 
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Figure 4.17 cPLA2α gene disruption protects against Ang II-induced renal 
oxidative stress 
 
NADPH oxidase activity measured in kidney homogenate (A), urinary TBARS (B), ROS 
production determined by DHE staining (C) quantified as fluorescence of 2-OHE (D) (n 
= 5-6 for all experiments; data are expressed as mean ± SEM) 
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Figure 4.18 Protection against Ang II-induced hypertension in cPLA2α-/- mice is 
independent of endothelin 
 
Endothelin levels measure by HPLC (n = 6 for all experiments; data are expressed as 
mean ± SEM) 
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CHAPTER 5.    DISCUSSION 
 
 
5.1 Aim 1. To Determine the Contribution of cPLA2α to Ang II-Induced 
Hypertension and Associated Cardiovascular Pathophysiology 
 
The novel finding of this study is the demonstration that cPLA2α is crucial for the 
development of Ang II-induced hypertension and associated cardiovascular dysfunction, 
hypertrophy, cardiac fibrosis, inflammation, oxidative stress, and activation of ERK1/2 
and cSrc in mice. This conclusion is based on my finding that infusion of Ang II 
increased SBP in cPLA2α+/+ mice and this was minimized by cPLA2α gene disruption. 
The selectivity of this effect of cPLA2α gene disruption in our mice was indicated by loss 
of cardiac expression of its mRNA but not that of other related PL enzymes: sPLA2α, 
cPLA2?, and cPLA2?; PLC?1, 2, 3, and 4; and PLD1 and PLD2. The protein expression 
of PLA2 but not PLCβ2, PLD1, or PLD2 was also absent in cPLA2α-/- mice. Since 
cPLA2α selectively catalyzes release of AA from tissue lipids227 and Ang II is known to 
activate cPLA2 to release AA, cPLA2 appears to mediate the hypertensive effect of Ang 
II via AA release. Supporting this view was our finding that cPLA2 activity, as indicated 
by its phosphorylation, was increased in the heart of cPLA2α+/+ but not cPLA2α-/- mice. 
The induction of eicosanoid production by lipopolysaccharide and calcium ionophore 
A23187 in peritoneal macrophages and furosemide-induced PGE2 excretion was also 
abolished in cPLA2α-/- mice.204,228,229 . In the present study, Ang II infusion increased the 
urinary output of PGEM. Moreover, administration of inhibitor of AA metabolism, 
ETYA, blocked Ang II-induced increase in SBP in cPLA2α+/+ mice. Therefore, it appears 
that metabolites of AA with pro-hypertensive effects contribute to the development of 
hypertension caused by this peptide in these mice. Since cPLA2α gene disruption or 
ETYA did not alter basal BP, it appears that cPLA2α activation and release of AA and its 
metabolites are not required to maintain basal BP. 
 
The increase in BP produced by Ang II in cPLA2α+/+ mice was associated with 
cardiac dysfunction as indicated by decreased EF, FS, CO and increased EDV and ESV, 
cardiac hypertrophy as shown by increased LV mass. These events were minimized in 
cPLA2α-/- mice, suggesting an essential role of cPLA2α+/+ in cardiac dysfunction and 
hypertrophy. Moreover, in the present study, cardiac fibrosis and inflammation as 
indicated by increased intracardiac staining of ?-SMA myofibroblasts, TGF-?, as well as 
by increased infiltration of F4/80+ macrophages and CD3+ T cells in Ang II-infused 
cPLA2α+/+ mice were prevented in cPLA2α-/- mice. These findings suggest that 
cPLA2α/AA also mediate cardiac fibrosis and inflammation associated with Ang II-
induced hypertension. cPLA2α was also found to be critical for increased vascular 
remodeling and reactivity associated with Ang II-induced hypertension characterized by 
an increase in various parameters such as media:lumen ratio, ?-SMA, deposition of 
collagen, as well as by increased contractile response of aorta to PE and ET-1 in 
cPLA2α+/+ but not cPLA2α-/- mice. Although the effect of Ang II on cardiovascular 
remodeling has been shown to be independent of an increase in BP,230-233 we cannot 
exclude the possibility that the protection against Ang II-induced cardiovascular 
remodeling in cPLA2α-/- mice could also be due to decreased BP. The precise mechanism 
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by which increase in BP causes cardiovascular remodeling is not known. Since stretch 
can increase cPLA2 activity and eicosanoid production234 and 20-HETE contributes to 
pressure-induced myogenic tone,235 it raises the possibility that the increased stretch 
associated with hypertension might also result in cPLA2α activation and generation of 
eicosanoids that contribute to  Ang II-induced cardiovascular remodeling. Ang II-induced 
hypertension is also known to be associated with endothelial dysfunction.16 Our finding 
that Ang II-induced endothelial dysfunction, as indicated by diminished relaxation of 
aorta to ACh but not to SNP, an agent that acts directly on VSMCs, occurs selectively in 
cPLA2α+/+ but not cPLA2α-/- mice, suggests that cPLA2α is essential for endothelial 
dysfunction associated with Ang II-induced hypertension. Moreover, endothelial 
dysfunction in larger vessels is dependent on NO.236 Hypertension caused by the inhibitor 
of NO synthesis, L-NG-nitroarginine methyl ester, which has been attributed to increased 
activity of RAS and sympathetic nervous system,237,238 is also associated with endothelial 
dysfunction in the aorta. Both hypertension and endothelial dysfunction are prevented in 
cPLA2α-/- mice.9 
 
The mechanism by which cPLA2α gene disruption protects against Ang II-
induced hypertension and cardiovascular remodeling, inflammation, increased vascular 
reactivity, and endothelial dysfunction could be due to alterations in expression of Ang II, 
Ang (1-7) receptors, and ACE enzyme. However, this possibility appears to be unlikely 
because the level of expression of AT1, AT2, Mas receptor and ACE enzyme examined 
in the heart were not different in cPLA2α-/- compared to cPLA2α+/+ mice. Oxidative stress 
and activation of immune system have been implicated in various models of hypertension 
including Ang II-induced hypertension.239,240 In the present study, Ang II-induced 
hypertension was associated with increased oxidative stress, as shown by increased 
cardiac NADPH oxidase activity, ROS production in the heart and aorta, and cardiac 
infiltration of F4/80+ macrophages and CD3+ T lymphocytes in cPLA2α+/+ mice. These 
changes were prevented in cPLA2α-/- mice, suggesting that increased oxidative stress and 
inflammation in Ang II-induced hypertension are dependent on cPLA2α. Supporting this 
view, it has been shown that Ang II increases NADPH oxidase activity by activating 
cPLA2 and release of AA in VSMCs.223,224 cPLA2α generated AA has also been 
implicated in NADPH oxidase activation in human monocytes and myeloid cell line 
PLB-985.241,242 AA metabolites generated by COX, PGE2 via its actions on EP1 and EP3 
receptors243,244 and TXA2245 contributes to Ang II-induced hypertension. AA metabolites 
formed by 12/15 LOX127,246 and by CYP450 4A (20-HETE),247,248 also contribute to Ang 
II-induced hypertension. Therefore, protection against Ang II-induced hypertension and 
associated cardiovascular pathogenesis in cPLA2α-/- mice is most likely due to lack of AA 
release and generation of one or more metabolites that mediate hypertensive effects of 
Ang II. Supporting this conclusion was our finding that Ang II infusion increased the 
urinary excretion of PGEM in cPLA2α+/+ but not cPLA2α-/- mice.  
 
The site of pro-hypertensive eicosanoids generated by cPLA2α that participate in 
Ang II-induced hypertension is not known. Since cPLA2α is ubiquitously distributed in 
various tissues and eicosanoids generated from AA act locally, it is possible that 
eicosanoids generated at the site of action of Ang II including the cardiovascular, renal, 
brain and cells of the immune system, could contribute to Ang II-induced hypertension. 
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Recently, it has been shown that Ang II by stimulating expression of (pro)renin receptor 
in the rat renal medulla through COX2-generated PGE2, via stimulation of EP4 receptors 
increases renin release that partly contributes to Ang II-induced hypertension.249 Also 
mice lacking macrophage 12/15 LOX have been shown to be resistant to L-NAME or 
DOCA-salt induced hypertension.250 Ang II is known to cause hypertension by increasing 
oxidative stress in subfornical organ (SFO) of circumventricular organs and via its 
projections to PVN and from there to the brain stem, finally resulting in increased 
sympathetic activity.251 cPLA2α is also present in the brain7,204 and 
intracerebroventricular administration of PGE2 increases sympathetic nervous activity, 
vasopressin release and BP.252 The demonstration that the effect of Ang II in increasing 
BP is mediated by activation of the EP1 receptor by PGE2, formed by COX-1 and not 
COX-2 in SFO, most likely by release of AA, suggests involvement of cPLA2.253 
Therefore, it is possible that Ang II-induced hypertension in our study could be mediated 
by activation of cPLA2α in the SFO as well as in the cardiovascular and renal systems. 
Moreover, it has been reported that Ang II-salt hypertension, which is associated with 
increased sympathetic activity and increased plasma levels of norepinephrine, are 
minimized by inhibitor of COX-1, SC560 but not nemsulide, an inhibitor of COX 2 
suggesting that COX-1 derived prostanoids by activating sympathetic nervous system 
increase BP.254 The oxidative stress produced by Ang II in SFO is mediated by ER stress, 
and inhibitors of ER stress minimize Ang II-induced hypertension.225 Activation of 
cPLA2 is associated with increased ER stress.255 Inhibitors of ER stress reduce BP in 
spontaneously hypertensive rats and the effect of endothelial-derived contractile factors, 
by suppressing H2O2 production and expression of COX-1 and ERK1/2 and cPLA2 
phosphorylation.256 However, our demonstration that cPLA2α gene disruption prevented 
the cardiac expression of ER stress markers p58IPK and CHOP suggests that Ang II also 
increases ER stress in the heart, but cPLA2α acts upstream of ER stress and NADPH 
oxidase activity, most likely by generating AA/metabolites. The effect of vasoactive 
agents, including Ang II, to promote influx of calcium and translocation of cPLA2α to the 
nuclear envelope/ER,257 the site of AA metabolizing enzymes (COX, LOX, and CYP 
P450),258-260 raises the possibility that cPLA2α via AA release and its metabolism by 
these enzymes might regulate generation of ER stress and ROS production. In support of 
this view, 12/15-LOX has been implicated in ER stress in adipocytes, pancreatic islets, 
and rat liver.259 
 
The increased ROS generated by Ang II promotes cardiovascular remodeling by 
activating one or more signaling molecules.59 Our finding that Ang II-induced 
hypertension was associated with increased cardiac ERK1/2 and cSrc activity in 
cPLA2α+/+ but not in cPLA2α-/- mice suggests that these signaling molecules are most 
likely activated by oxidative stress produced by cPLA2α-generated AA metabolites, thus 
contributing to cardiovascular remodeling.  
 
In conclusion, the present study provides the first evidence that the selective 
release of AA by cPLA2α is crucial for the development of Ang II-induced hypertension 
and associated cardiovascular pathophysiological changes including cardiovascular 
remodeling, increased vascular reactivity, endothelial dysfunction, and cardiac 
inflammation. These effects are most likely mediated by oxidative16,59,166 and ER 
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stress225,256 generated by AA metabolism259 and predominantly by pro-hypertensive 
eicosanoids resulting in activation of one or more signaling molecules including ERK1/2 
and cSrc.  
 
However, further studies using tissue specific knockout of cPLA2α and AA 
metabolizing enzymes would allow assessment of their relative contribution in various 
tissues to Ang II- and other models of hypertension and associated pathogenesis.  
 
 
5.2 Aim 2. To Investigate if cPLA2α Is Essential for Renal Dysfunction and End 
Organ Damage Associated with Ang II-Induced Hypertension 
 
This study demonstrated that cPLA2? that selectively stimulates release of AA 
from tissue lipids is indispensable for renal dysfunction, inflammation, and end organ 
damage associated with Ang II-induced hypertension, most likely as a result of increased 
production and/or action predominantly of pro-hypertensive eicosanoids and generation 
of ROS. Eicosanoids generated from AA released by cPLA2, in various structures of the 
kidney by their direct vascular, as well as tubular-glomerular actions, and, more 
importantly by modulating and/or mediating the actions of various neurohumoral agents 
contribute to renal anti- and pro-hypertensive mechanisms.126,127,243,244,261-265 This study 
showed that the net effect of eicosanoids that contribute to renal pro-hypertensive 
mechanism and associated renal dysfunction and end organ damage predominates over 
those that participate in anti-hypertensive mechanisms in Ang II-induced hypertension. 
Infusion of Ang II increased SBP in cPLA2?+/+, but not in cPLA2?-/-, mice. In the present 
study, Ang II infusion also increased renal cPLA2 activity, as indicated by its 
phosphorylation, without altering its expression in cPLA2?+/+, but not cPLA2?-/- mice. 
This observation together with the demonstration that Ang II increases urinary output of 
AA metabolites in cPLA2?+/+, but not cPLA2?-/- mice, and cPLA2? gene disruption also 
inhibits the basal, as well as furosemide-induced, increase in urinary PGE2 excretion,229 
suggest that eicosanoids generated by Ang II in the kidney are most likely due to AA 
release consequent to activation of cPLA2?.  
 
 It has been shown that cPLA2 gene disruption does not alter renal function as 
indicated by lack of changes in serum electrolyte or creatinine concentration, glomerular 
filtration rate, and fractional Na+ or K+ excretion compared to cPLA2+/+ mice; however, 
cPLA2 gene disruption produces concentration defect in older cPLA2-/- mice (>45 
weeks).229 In the present study, cPLA2 gene disruption alone did not alter renal function 
in 9 to 10 week old mice or cause any structural changes. However, in the present study 
Ang II-induced increase in renal arterial resistance and pulsatility observed in cPLA2?+/+ 
mice was prevented in cPLA2?-/- mice. These observations suggest that one or more AA 
metabolites predominantly with pro-hypertensive effects mediate the increase in renal 
vascular resistance caused by Ang II in cPLA2+/+ mice. Supporting this view is the report 
that inhibitor of AA metabolism ETYA acid attenuates Ang II-induced renal 
vasoconstriction266 and the COX product, PGE2, via activation of EP1 and EP3 receptor, 
and PGH2 and thromboxane A2 via thromboxane-prostanoid receptor, contributes to 
pressor actions of Ang II.245 A recent study demonstrated Ang II-mediated activation of 
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EP4 receptor via COX-2 derived PGE2 increases expression of (pro)renin receptor 
locally in rat renal medulla and increases medullary and urinary activity of renin that 
partly contributes to Ang II-induced hypertension.267 Products of AA generated via LOX 
(12-HETE) and cytochrome P450 4A (20-HETE) also mediate Ang II-induced renal 
vasoconstriction.248,268,269 In the present study, infusion of Ang II for 13 days in 
cPLA2?+/+ mice also increased water intake, urine output, and glomerular filtration rate; 
decreased urinary osmolality; and caused proteinuria in cPLA2?+/+ mice. Since all these 
effects of Ang II were minimized in cPLA2?-/- mice, they are most likely mediated by 
AA metabolites that contribute predominantly to pro-hypertensive mechanisms. The 
cPLA2?-dependent dipsogenic effect of Ang II could be mediated by the central actions 
of AA metabolite, Tx A2, because Tx A2 receptor blocker inhibits and Tx A2 receptor 
activation enhances the effect of intracerebroventricularly administered Ang II.270 Ang II 
stimulates the production of eicosanoids with both pro- and antihypertensive actions, and 
the balance between their vascular, as well as tubular actions, most likely maintain renal 
homeostasis.126,127,248,261-265,271 Therefore, it appears that renal dysfunction associated with 
Ang II-induced hypertension is primarily due to loss of predominantly those eicosanoids 
that contribute to pro- and not anti-hypertensive mechanisms. Since nonsteroidal anti-
inflammatory COX-2 inhibitors or COX gene disruption produce renal dysfunction and 
hypertension in mice on a high salt diet due to loss of anti-hypertensive and reno-
protective effect of PGI2,271 further studies in cPLA2?-/- mice on low and high salt diets 
and other models of hypertension would allow assessment of the role of anti-hypertensive 
eicosanoids including PGI2 and EETs in renal function. 
 
cPLA2α is also present in immune cells, and AA released by its activation is 
metabolized into eicosanoids with pro- and anti-inflammatory properties and is able to 
generate cytokines/chemokines, which regulate both innate and adaptive immune 
responses.272-277 In this study, infusion of Ang II for 13 days in cPLA2?+/+ mice caused 
inflammation as demonstrated by increased renal infiltration of F4/80+ macrophages and 
CD3+ T lymphocytes and damage as indicated by renal accumulation of ?-smooth muscle 
actin, TGF?, and collagen. Our findings that Ang II infusion failed to produce these 
effects in cPLA2?-/- mice suggest that AA released by cPLA2? activation results in 
production of predominantly pro-hypertensive eicosanoids that stimulate infiltration of 
macrophages and CD3+ T lymphocytes in the kidney and promote production of 
cytokines/chemokines and inflammation and renal fibrosis.  
 
 The effect of cPLA2? gene disruption to minimize Ang II-induced renal 
dysfunction, renal damage, and inflammation without altering basal renal function 
suggests that cPLA2α activity and hence the amount of AA released under basal 
physiological conditions is low and does not appear to generate a sufficient amount of 
eicosanoids to affect renal function. Supporting this view, it has been shown that, 
although cPLA2 is constitutively active, it requires influx of extracellular calcium for its 
translocation to the nuclear envelope and phosphorylation by one or more kinase for its 
maximal activity to release AA.187,272 Several vasoactive agents that increase influx of 
extracellular calcium, including Ang II, increase cPLA2 activity.10,11,278,279 In the present 
study, Ang II increased cPLA2 activity in the kidney, as measured by its phosphorylation 
and as shown from the elevated urinary excretion of AA metabolite PGEM in  
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cPLA2? +/+, but not cPLA2?-/-, mice. Therefore, the increase in cPLA2 activity observed 
in ischemia,204,280 diabetic nephropathy,281 glomerulonephritis,282 and polycystic kidney 
disease283 is most likely due to associated increase in the activity of various vasoactive 
systems including the renin-angiotensin system.284-287 Increased levels of Ang II would 
result in increased calcium influx in various renal cell types, AA release, and generation 
of eicosanoids that favor renal pro-hypertensive mechanisms and contribute to renal 
dysfunction, inflammation, and end-organ damage. 
 
 The mechanism by which cPLA2? gene disruption minimizes Ang II-induced 
renal dysfunction, inflammation, and end-organ damage could be the consequence of 
decreased BP.288 The mechanical stretch and inflammation, which are associated with 
hypertension, promote aortic stiffening via activation of p38 MAPK.289 The mechanical 
stretch increases Ca2+ influx via stress-operated Ca2+ channels, which is known to 
increase cPLA2 activity and generation of eicosanoids,234 and metabolites of AA increase 
p38 MAPK activity.290 Therefore, it is possible that the effect of mechanical stretch 
caused by high BP on cardiovascular remodeling, activation of immune cells, and end-
organ damage might be mediated in part by pro-hypertensive eicosanoids. However, Ang 
II also produces cardiovascular and renal pathophysiological changes independent of 
increased BP.232,233 In transgenic rats carrying both human renin and angiotensinogen 
genes, treatment with triple therapy (hydralazine, reserpine, and hydrochlorothiazide) 
prevented increased BP but not end organ damage, inflammation, or cellular growth in 
the kidney.233 Therefore, the protection against Ang II-induced renal dysfunction, 
inflammation, and damage could also result from a pressure-independent mechanism. ET 
has been implicated in Ang II-induced hypertension and some of its renal actions.267,291 
However, in our study, ET was unlikely to mediate cPLA2?-dependent actions of Ang II 
because it produced an equally insignificant increase in the plasma levels of ET in 
cPLA2?-/- and cPLA2? +/+ mice. 
 
Ang II is known to increase oxidative stress, activate immune cells that release 
cytokines, and promote inflammation that have been implicated in the development of 
hypertension and end organ damage.15,292,293 These finding that cPLA2? gene disruption 
prevented Ang II-induced increase in NADPH oxidase activity, generation of ROS and 
TBARS, byproducts of lipid peroxidation in the kidney, suggest that ROS/lipid peroxides 
generated by renal and immune cells by AA most likely contribute to renal dysfunction, 
inflammation, and end organ damage. Supporting this view are the reports that a) 
monocytes/macrophages and T cells express cPLA2α273 and NADPH oxidase,241,294,295 b) 
AA is required for activation of NADPH oxidase and generation of ROS in 
monocyte/macrophages and VSMCs,12,241,294 and c) ROS and/or one or more AA 
metabolites stimulate release of cytokines that promote inflammation.296,297  
 
 In conclusion, this study demonstrated that cPLA2α is essential for the 
development of renal dysfunction, inflammation, and end organ damage associated with 
Ang II-induced hypertension. AA released by cPLA2α activation by Ang II, most likely 
via generation of pro-hypertensive eicosanoids, and ROS/lipid peroxides promote renal 
dysfunction, activation of immune cells leading to inflammation, and end- organ damage. 
Therefore, cPLA2α could serve as a potential novel target for developing therapeutic 
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agents for treating hypertension and associated renal dysfunction and end organ damage. 
Moreover, the development of water-soluble selective cPLA2α inhibitors would allow 
further assessment of its physiological and pathophysiological significance in kidney 
diseases and other models of hypertension 
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CHAPTER 6.    CONCLUSION 
 
 
This study has demonstrated that cPLA2α is essential for the development of Ang 
II-induced hypertension and associated cardiovascular remodeling, cardiac and 
endothelial dysfunction, and increased vascular reactivity. Cardiac oxidative and ER 
stress and inflammation associated with Ang II-induced hypertension also depends on 
cPLA2α. Ang II-induced cardiac dysfunction, remodeling, and inflammation that depend 
on cPLA2α are most likely mediated by ERK1/2 and cSrc. My study provides novel 
information on the mechanism of Ang II-induced hypertension and associated 
cardiovascular pathophysiological changes, whereby cPLA2α-generated AA is crucial for 
Ang II-induced hypertension.  
 
These findings also suggest that cPLA2α gene disruption in mice minimizes Ang 
II-induced increase in renal vascular resistance and renal dysfunction, inflammation, and 
end organ damage.cPLA2α gene disruption also prevents the effect of Ang II to increase 
renal NADPH oxidase activity, ROS, and TBARS production. cPLA2α plays a critical 
role in renal dysfunction, inflammation, and end-organ damage associated with Ang II-
induced hypertension, most likely as a result of release of AA and generation of pro-
hypertensive eicosanoids and ROS/lipid peroxides. 
 
This study and the work of other investigators that has been discussed in this 
dissertation has led us to propose the following mechanism of cPLA2α dependent Ang II- 
induced hypertension and associated pathophysiology. (Figure 6.1) AA and or its 
metabolites generated via cPLA2α, activates the immune system resulting in immune cell 
infiltration and inflammation in cardiovascular and renal tissues. Cytokines released by 
these infiltrating cells, results in elevation of BP and also ROS production. The 
metabolites of AA may also cause ER stress which is known to promote ROS production 
resulting in hypertension. ROS, via activation of second messenger systems, ERK1/2 and 
cSrc results in cardiovascular and renal hypertrophy and dysfunction promoting 
hypertension. Hypertension may in turn exacerbate end organ dysfunction and damage. 
 
These observations raise the possibility that cPLA2α could serve as a target for 
developing novel therapeutic agents to treat hypertension and associated renal 
dysfunction and end organ damage. 
  
 63 
 
 
Figure 6.1 Proposed mechanism of cPLA2α dependent Ang II-induced 
hypertension and associated pathophysiology 
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